All conditions

Stomach Cancer

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

3116
Trials on record
570
Recruiting now
27
Australian sites
59
Phase 3 trials
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Stomach Cancer →

Get alerts when Stomach Cancer trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Stomach Cancer

Stomach cancer, also known as gastric cancer, is a condition where abnormal cells grow and multiply in the lining of the stomach. Over time, these cells can form a tumour. The stomach is part of the digestive system, sitting in the upper left area of the abdomen, and it plays an important role in breaking down food. Stomach cancer can affect different parts of the stomach, and the type and location of the cancer can influence how it behaves and how it is managed.

In Australia, stomach cancer is not among the most common cancers, but it does affect a significant number of people each year. It is diagnosed more often in men than women, and it tends to be found in people over the age of 60, though it can occur at any age. People with a family history of the condition, those who have had a longstanding infection with a bacteria called Helicobacter pylori, and people of some Asian, South American, or Eastern European backgrounds may have a higher likelihood of developing it.

Treatment for stomach cancer in Australia generally depends on factors such as the size and stage of the cancer, its location, and a person's overall health. A team of specialists is typically involved in planning care, which may include surgeons, oncologists, and other health professionals. Common treatment approaches can include surgery to remove part or all of the stomach, chemotherapy, radiation therapy, or targeted drug therapies — and sometimes a combination of these. Your medical team is the best source of information about what options may be relevant to your specific situation.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Stomach Cancer in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

Research pipeline

Where trials for Stomach Cancer currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Stomach Cancer.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Stomach Cancer by country. Australia is highlighted.

Showing the top 10 of 60 countries with trial sites.

Clinical trials for Stomach Cancer

Showing 580 of 580 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT02052778 · Taiho Oncology, Inc. Phase 2 · 13 countries Completed
Completed Phase 2 Est. completion 1 October 2020
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE Hong Kong🇮🇹 IT🇯🇵 JP🇳🇱 NL +5 more

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with cancer that has spread or cannot be surgically removed, confirmed by a lab test on a tissue or cell sample - You are willing and able to sign a consent form agreeing to take part - Your cancer has continued to g...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02935634 · Bristol-Myers Squibb Phase 2 · 9 countries Completed
Completed Phase 2 Est. completion 11 May 2022
🇦🇺 AU🇨🇦 CA🇩🇪 DE🇮🇱 IL🇮🇹 IT🇳🇱 NL🇸🇬 SG🇨🇭 CH +1 more

**Who might be able to join this trial:** - You have been diagnosed with esophageal cancer, stomach cancer, or cancer at the junction between the esophagus and stomach that cannot be removed by surgery, has spread locally, or has spread to other parts of the body, and the cancer type has been confirmed by a tissue samp...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03126110 · Incyte Biosciences International Sàrl Phase 2 · 4 countries Completed
Completed Phase 2 Est. completion 9 November 2021
🇦🇺 AU🇧🇪 BE🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - Your cancer has spread to nearby areas or other parts of the body, and surgery to fully remove it is not possible. - (Phase 1 only) You have any type of advanced or metastatic solid tumor cancer. - (Phase 1 only) Your cancer has continued to grow or spread after trying avail...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03150810 · BeiGene Phase 1 · 4 countries Completed
Completed Phase 1 Est. completion 4 May 2023
🇦🇺 AU🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older and have an advanced or spreading (metastatic) solid tumour cancer - You are relatively active and able to carry out daily activities with little or no limitation (confirm with trial site for exact fitness level required) - Your cancer can be...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03615326 · Merck Sharp & Dohme LLC Phase 3 · 20 countries Completed
Completed Phase 3 Est. completion 20 March 2024
🇦🇺 AU🇧🇷 BR🇨🇱 CL🇨🇳 CN🇫🇷 FR🇩🇪 DE Guatemala🇮🇪 IE +12 more

**Who might be able to join this trial:** - You have been diagnosed with stomach cancer or cancer of the junction between the stomach and food pipe (gastroesophageal junction) that has spread or cannot be removed by surgery, and you have not yet received treatment for it - Your cancer has been confirmed by a lab test...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03675737 · Merck Sharp & Dohme LLC Phase 3 · 33 countries Completed
Completed Phase 3 Est. completion 3 October 2022
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇳 CN🇨🇴 CO Costa Rica +25 more

Who might be able to join this trial: - People who have been diagnosed with locally advanced, inoperable, or metastatic stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed through a tissue or cell sample, with known PD-L1 test results. - People whose cancer has tested negative for a protei...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04879368 · Australasian Gastro-Intestinal Trials Group Phase 3 · 9 countries Completed
Completed Phase 3 Est. completion 14 January 2025
🇦🇺 AU🇦🇹 AT🇩🇪 DE🇮🇹 IT🇯🇵 JP🇰🇷 KR🇪🇸 ES🇹🇼 TW +1 more

**Who might be able to join this trial:** - Adults aged 18 or older who have gastro-oesophageal cancer (starting in the stomach or the junction between the oesophagus and stomach) that has spread to other parts of the body or has come back in the local area, and where the cancer type is adenocarcinoma or undifferentia...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04895709 · Bristol-Myers Squibb Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 31 August 2031
🇦🇺 AU🇨🇦 CA🇩🇪 DE🇮🇱 IL🇮🇹 IT🇯🇵 JP🇪🇸 ES🇺🇸 US

Who might be able to join this trial: - Participants must be willing to provide tumor tissue samples before treatment begins and again during treatment, for research testing. - Participants must have measurable tumors that can be seen on scans, and at least one tumor that can be safely biopsied with a needle (note: fin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05150691 · DualityBio Inc. Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 1 April 2026
🇦🇺 AU🇨🇳 CN Puerto Rico🇰🇷 KR🇹🇼 TW🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a HER2-positive or HER2-expressing solid tumour (a tumour that has spread or cannot be surgically removed) that has not responded to standard treatment, cannot be tolerated with standard treatment, or for which no standard treatment exists...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05267626 · Aulos Bioscience, Inc. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 12 June 2026
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - Your cancer must be measurable on a CT scan and/or MRI scan using specific medical measurement standards. - You may be eligible if you have skin melanoma (cutaneous melanoma) that cannot be surgically removed or has spread to other parts of the body, and your cancer has cont...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05427487 · ImmVirx Pty Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2028
🇦🇺 AU

**Who might be able to join this trial:** - People who have been diagnosed with advanced colorectal cancer, stomach/gastroesophageal cancer, or ovarian cancer that has gotten worse or is no longer responding to standard treatments. For colorectal cancer, lab tests must show the tumor has a specific characteristic call...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05523947 · Yuhan Corporation Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 31 March 2028
🇦🇺 AU🇰🇷 KR🇺🇸 US

**Who might be able to join this trial:** *For the Dose Escalation part of the trial:* - People whose cancer has been confirmed by laboratory testing to be HER2-positive (a specific protein found on some cancer cells) - People who are able to provide a sample of their tumor tissue *For the Dose Expansion part of the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05581004 · Genentech, Inc. Phase 1 · 10 countries Recruiting
Recruiting Phase 1 Est. completion 31 July 2028
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇬🇷 GR🇳🇱 NL🇰🇷 KR🇪🇸 ES🇸🇪 SE +2 more

**Who might be able to join this trial:** - Doctors expect you to live for at least 12 weeks or more. - You are generally able to carry out daily activities with little or no limitation (confirm with trial site for specific fitness level required). - You have areas of cancer in your body that can be measured on scans....

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05804331 · Western Sydney Local Health District Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 March 2028
🇦🇺 AU

**Who might be able to join this trial:** - People aged 18 years or older. - People who have a growth or abnormal tissue in the upper digestive tract (such as the stomach or oesophagus) that is larger than 10mm, and where the growth is located in one of the following layers of the digestive tract wall: the inner lining...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT05872295 · Iksuda Therapeutics Ltd. Phase 1 · 4 countries Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇦🇺 AU🇳🇿 NZ🇸🇬 SG🇺🇸 US

**Who might be able to join this trial:** - People who have a solid tumour (cancer) that tests positive for a protein called HER2, at various levels of expression (ranging from high to low, based on specific lab test results) - People with hormone receptor-positive breast cancer who have previously been treated with a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05969041 · Myeloid Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 August 2027
🇦🇺 AU

**Who might be able to join this trial:** - Adults aged 18 or older at the time of signing the consent form - People who have been confirmed by tissue testing to have metastatic or advanced cancer of one of the following types: urothelial, cervical, ovarian epithelial, triple-negative breast, HR+/HER2- breast, pancrea...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06219941 · AstraZeneca Phase 2 · 14 countries Recruiting
Recruiting Phase 2 Est. completion 11 August 2026
🇦🇺 AU🇨🇦 CA🇨🇳 CN🇬🇪 GE🇯🇵 JP🇲🇾 MY Moldova🇵🇱 PL +6 more

**Who might be able to join this trial:** **Criteria that apply to all parts of the trial:** - Adults aged 18 or older (or the legal age of consent in their country) at the time of signing the consent form. - People whose cancer tests positive for a protein called CLDN18.2. - People who have at least one tumour that c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06242470 · MacroGenics Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 1 May 2028
🇦🇺 AU🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who are able to give informed consent - People whose general health and blood test results meet the required standards set by the trial - People who have a stored tumour tissue sample available, or who are able to have a fresh tumour biopsy taken; peo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06330064 · Daiichi Sankyo Phase 2 · 18 countries Recruiting
Recruiting Phase 2 Est. completion 25 July 2028
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇱 CL🇫🇷 FR🇩🇪 DE🇮🇪 IE +10 more

Who might be able to join this trial: **All participants must meet these general criteria:** - People who have at least one tumour lesion that has not been previously treated with radiation and can be safely biopsied, or who have an archived tumour tissue sample taken within the last 6 months after their cancer worsen...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06337084 · Monopar Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 April 2026
🇦🇺 AU

**Who might be able to join this trial:** - People who have been diagnosed with a solid tumour cancer, confirmed through a tissue or cell sample. - People who are 18 years of age or older. - People who have at least one tumour measuring 1 cm or more visible on a recent PET/CT scan (a type of imaging scan). A small num...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06532006 · Shanghai Henlius Biotech Phase 3 · 17 countries Recruiting
Recruiting Phase 3 Est. completion 1 June 2027
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇱 CL🇨🇳 CN🇬🇪 GE🇩🇪 DE🇬🇷 GR +9 more

**Who might be able to join this trial:** - Adults aged 18 or older at the time of signing the consent form - People with a confirmed diagnosis (through tissue or cell testing) of HER2-positive stomach or gastroesophageal junction cancer that has not been treated before, and that has either spread to nearby areas and...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06617169 · Monopar Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇦🇺 AU

Who might be able to join this trial: - People who previously took part in the MNPR-101-D001 study. - Women who could become pregnant must have a negative pregnancy blood test at the screening visit, and a negative pregnancy urine test on the first day of treatment if screening took place more than 7 days earlier. - Bo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06730750 · Bristol-Myers Squibb Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 5 September 2026
🇦🇺 AU🇨🇦 CA🇺🇸 US

Who might be able to join this trial: - People who have an advanced solid tumour that has been confirmed by a tissue or cell sample, cannot be removed by surgery or has spread to other parts of the body, and can be measured using standard imaging methods - People with colorectal cancer (bowel cancer) that is advanced,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06731478 · Daiichi Sankyo Phase 3 · 26 countries Recruiting
Recruiting Phase 3 Est. completion 1 June 2028
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇳 CN +18 more

**Who might be able to join this trial:** - You must be willing to sign consent forms before any trial-related testing or procedures begin. - You must be 18 years of age or older when you sign the consent form. - You have stomach (gastric) or gastroesophageal junction (GEJ) cancer that cannot be removed by surgery and...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06760819 · Bayer Phase 2 · 11 countries Recruiting
Recruiting Phase 2 Est. completion 3 February 2027
🇦🇺 AU🇨🇦 CA🇨🇳 CN🇩🇰 DK🇫🇷 FR🇮🇹 IT🇯🇵 JP🇰🇷 KR +3 more

**Who might be able to join this trial:** - People who have been diagnosed with a locally advanced, inoperable, or metastatic solid tumour cancer confirmed by a tissue or cell sample — specifically colorectal, biliary tract, bladder or urothelial tract, cervical, endometrial, breast, or other solid tumour cancers (not...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06764875 · AstraZeneca Phase 3 · 28 countries Recruiting
Recruiting Phase 3 Est. completion 27 April 2029
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇳 CN +20 more

**Who might be able to join this trial:** - People whose gastric cancer tumour tests positive for a protein called HER2. - People whose tumour has a PD-L1 combined positive score (CPS) of 1 or higher — a measure of how much of a certain protein is present in the tumour (confirm with trial site if unsure what this mean...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06789172 · Epkin Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 1 July 2028
🇦🇺 AU🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People who have a confirmed advanced or spreading cancer (proven by tissue or cell testing), where the specific cancer type and treatment history match the requirements for either the early-phase portion or one of the four specific cancer groups (sarcoma, non-small cell lung...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06901531 · Astellas Pharma Global Development, Inc. Phase 3 · 22 countries Recruiting
Recruiting Phase 3 Est. completion 30 September 2028
🇦🇺 AU🇧🇪 BE🇧🇷 BR🇨🇱 CL🇨🇳 CN🇨🇿 CZ🇫🇷 FR🇩🇪 DE +14 more

**Who might be able to join this trial:** - People who have been diagnosed with stomach (gastric) or gastroesophageal junction (GEJ) cancer that has been confirmed by tissue testing (biopsy). - People whose cancer has been confirmed by imaging scans to be advanced, unable to be removed by surgery, or has spread to oth...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06910657 · ViroMissile, Inc. Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 31 January 2027
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older. - People with advanced solid tumour cancers that have been confirmed by laboratory testing of tissue or cell samples, where the cancer has continued to grow despite standard treatment, or where no standard treatment exists. - People who are largely a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06921837 · Bolt Biotherapeutics, Inc. Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇦🇺 AU🇰🇷 KR🇹🇼 TW

Who might be able to join this trial: - The cancer must have areas that can be measured using standard imaging assessment tools (confirm with trial site). - People with stomach cancer or cancer of the junction between the stomach and oesophagus that has either spread to other parts of the body (Stage 4) or cannot be re...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06974110 · MOMA Therapeutics Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 November 2027
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have an advanced or spreading solid tumor cancer that cannot be removed by surgery, and it has been confirmed by lab testing to have specific genetic markers called MSI-H or dMMR - You have previously been treated with a type of immunoth...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07070232 · BioNTech SE Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 1 March 2028
🇦🇺 AU🇧🇪 BE🇩🇪 DE🇮🇹 IT🇪🇸 ES Turkey (Türkiye)🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older at the time of signing the consent form (or older if local laws require a higher age of consent). - People whose cancer has been confirmed by lab testing of a tissue or cell sample, and whose disease has either spread to other parts of the body or has...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07115043 · AstraZeneca Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 2 October 2029
🇦🇺 AU🇯🇵 JP🇰🇷 KR🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You are generally able to carry out daily activities with little or no difficulty (your doctor can confirm your activity level score) - You can provide a stored sample of your tumor tissue - You have at least one tumor that can be measured...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07262619 · Eikon Therapeutics Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 March 2029
🇦🇺 AU🇳🇿 NZ🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form - People who are expected to live for at least 3 months - People who have an advanced solid tumour (one that cannot be removed by surgery and/or has spread to other parts of the body), confirmed...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02020252 · University of Chicago Not Applicable · 1 country Completed
Completed Not Applicable Est. completion 1 December 2018
🇺🇸 US

Who might be able to join this trial: - You are an adult (18 or older) - You speak English - You are a woman or a man - You have recently been diagnosed with lung, gastric (stomach), or pancreatic cancer - You are attending your first oncology (cancer care) appointment at the University of Chicago outpatient oncology c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07268469 · European Institute of Oncology Not Applicable Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 1 July 2033

**Who might be able to join this trial:** - You are 18 years of age or older - You are able to agree to take part and sign a consent form - You have been assessed as suitable for surgery that aims to remove or cure your cancer, even if you have already received some treatment before surgery (such as chemotherapy) - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07429487 · Centre Antoine Lacassagne Not Applicable · 1 country Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 15 September 2029
🇫🇷 FR

Who might be able to join this trial: - You are between 18 and 75 years old - You have been diagnosed with a specific type of cancer (breast, colorectal, ovarian, pancreatic, biliary, or gastric) that has not spread to other parts of the body, confirmed by a tissue test - You finished your course of chemotherapy (not i...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00722228 · Hadassah Medical Organization Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2025
🇮🇱 IL

Who might be able to join this trial: - You have one of the following cancers that has spread to other parts of the body: melanoma (skin cancer), breast, ovarian, colorectal (bowel), stomach, lung, or kidney cancer - You are 18 years of age or older - You have already tried at least one chemotherapy treatment that did...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00899626 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2045
🇺🇸 US

Who might be able to join this trial: - People who are scheduled to have a colonoscopy or endoscopy for diagnostic or screening reasons at Vanderbilt University Medical Center or the Veterans Affairs Medical Center - People who have been diagnosed with a gastrointestinal (digestive tract) cancer, polyps, or inflammator...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01048281 · Stanford University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2099
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with stomach or esophageal (food pipe) cancer, OR people who have a higher-than-normal hereditary (family-linked) risk of developing cancer in the upper digestive tract Who may not be able to join: - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01416714 · University of Chicago Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with one of the following cancers and need to have a surgery or a diagnostic procedure (a test or examination to investigate your condition): stomach cancer, food pipe (esophageal) cancer, pancreatic cancer, liver cancer, gallbladder cancer, gastrointestin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01514045 · Stanford University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a stomach tumor (including tumors where the stomach meets the food pipe), confirmed by a tissue sample test - OR a close family member (parent, sibling, child, grandparent, aunt, uncle, niece, or nephew) has had stomach cancer - OR you have been told...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01915225 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2035
🇺🇸 US

Who might be able to join this trial: - People aged 2 years or older (note: children aged 2 to 17 may only participate in the sample collection part if tissue is collected during a surgery that is already being done for medical reasons, and the sample collection — such as blood, urine, or tissue — does not add any extr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01917552 · Asan Medical Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 August 2026
🇰🇷 KR

Who might be able to join this trial: - People who have had surgery to fully remove stomach cancer or cancer at the junction between the stomach and the food pipe, with the aim of curing the disease - People whose cancer is classified as stage IB (using a specific medical staging system) and who also have at least one...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT01935778 · Asan Medical Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2028
🇰🇷 KR

Who might be able to join this trial: - People who have given written consent to participate in the study before it begins - People who have been newly and definitively diagnosed with a type of stomach cancer (gastric adenocarcinoma) or cancer at the junction of the stomach and oesophagus (gastroesophageal junction ade...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02047994 · International Agency for Research on Cancer Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2033
🇱🇻 LV

Who might be able to join this trial: - People who are between 40 and 64 years old at the time of signing the consent form - People who are willing to take part in the study regardless of which group they are assigned to, after being fully informed about the possible benefits and risks - People who have signed the cons...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT02139605 · Tata Memorial Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2025
🇮🇳 IN

Who might be able to join this trial: - People who are in good enough physical health to undergo surgery, as assessed at a pre-surgery medical check (with a fitness score of 0 or 1 on a standard medical scale) - People who have been confirmed through a tissue biopsy to have stomach cancer of a specific type called aden...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02333604 · Cancer Support Community, Research and Training Institute, Philadelphi... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2035
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with cancer, OR you are a family member or friend who has cared for someone with a cancer diagnosis - You currently live in the United States, a US territory, or Canada - You are able to read and understand English Who may not be able to join: - There are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02491840 · University Hospital, Strasbourg, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2029
🇫🇷 FR

Who might be able to join this trial: - You have been diagnosed with stomach cancer (adenocarcinoma) or cancer at the junction between the stomach and the food pipe (cardia adenocarcinoma), in any location - You are older than 18 years of age - Your general health and ability to carry out daily activities is at an acce...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02495337 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇨🇦 CA

Who might be able to join this trial: - People who have been diagnosed with cancer of the esophagus or stomach, and/or a condition called GERD (acid reflux disease) with or without Barrett's esophagus (a change in the lining of the food pipe often linked to long-term acid reflux), and who are already scheduled to have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02526095 · University Hospital, Lille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who have been diagnosed with esophageal cancer, gastric (stomach) cancer, or cancer at the junction between the esophagus and stomach, confirmed by biopsy, regardless of the cancer type, stage, or planned treatment - People who have not yet received any treatment for t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02838836 · University of Missouri-Columbia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

Who might be able to join this trial: - You must be 18 years old or older. - People of any gender or ethnic background are welcome. - You have been diagnosed with one of the following solid cancers at any stage: lung, esophageal, stomach, bile duct/pancreas, colorectal, melanoma, or sarcoma. - You may also be eligible...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02869477 · Institut Paoli-Calmettes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with cardia cancer (a type of cancer located at the junction where the esophagus meets the stomach) Who may not be able to join: - No specific exclusion criteria have been listed for this trial (confirm with trial site) Important: Always verify el...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03093688 · Shanghai Public Health Clinical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2030
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with advanced lung cancer, advanced stomach cancer, advanced pancreatic cancer, liver cancer (hepatocellular carcinoma), or advanced colorectal cancer, confirmed by laboratory testing of tissue or cells - People whose saved tumour tissue sample...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03190941 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 29 June 2027
🇺🇸 US

**Who might be able to join this trial:** - The cancer must be measurable, spread to other parts of the body or unable to be surgically removed, and must carry a specific gene mutation called G12V in the KRAS, NRAS, or HRAS gene, confirmed by an approved laboratory test. - People must have a specific immune system mar...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03221335 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
Hong Kong

**Who might be able to join this trial:** - People aged 18 years or older - People who have a solid tumour (cancer or growth) in the stomach, liver, kidney, or adrenal glands that is smaller than 5cm at its widest point and has been identified as needing treatment - People who are not suitable for surgery for one or m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03250091 · University of Latvia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇱🇻 LV

Who might be able to join this trial: - You are scheduled to have an upper endoscopy (a procedure where a camera is passed down your throat to look at your stomach and digestive tract) - You are willing and motivated to take part in the study - You are able to sign a consent form agreeing to participate Who may not be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03259867 · Teclison Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with either advanced liver cancer (hepatocellular carcinoma/HCC) or stomach cancer that has spread to other parts of the body (metastatic gastric cancer) - You are between 18 and 80 years old - If you have liver cancer (HCC): your cancer has continued...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03385018 · Yonsei University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2022
🇰🇷 KR

**Who might be able to join this trial:** - People who are between 20 and 80 years old - People who are generally well enough to carry out daily activities with little or no limitation (as measured by a standard medical scale called ECOG, at level 0 or 1) - People whose overall physical health is rated as suitable for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03463668 · Institut Paoli-Calmettes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2029
🇫🇷 FR

**Who might be able to join this trial:** - You have a narrowing (blockage) in the first part of your small intestine (called the duodenum) that is causing symptoms, and you received a tube/stent placed in that area to help keep it open between the years 2010 and 2017. **Who may not be able to join:** - Your narrowing...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03526835 · Merus B.V. Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 1 November 2025
🇧🇪 BE🇫🇷 FR🇳🇱 NL🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed (by lab testing of tissue or cells) to have a solid tumour that has spread to other parts of the body or cannot be surgically removed, and where standard curative treatment is no longer an option. - People who are able to provide a fresh tumour...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03539822 · Anwaar Saeed Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older. - People who are generally well enough to carry out light activity and care for themselves (a doctor would assess this using a standard performance scale scored 0 or 1). - People who have been confirmed by tissue testing to have one of the following...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03551951 · University of Missouri-Columbia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2027
🇺🇸 US

Who might be able to join this trial: - You must be older than 18 years old. - People of any gender or ethnicity may participate. - You may be eligible if you have been diagnosed with a solid cancer (such as lung, esophageal, stomach, bile duct/pancreas, bowel, melanoma, or sarcoma) at any stage. - People without any h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03614650 · Shenzhen Geno-Immune Medical Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have signed a written consent form before any study procedures begin. - People whose cancer tissue samples test positive for at least one of a specific set of proteins found on tumour cells (such as GD2, mesothelin, CEA, P16, MMP, Melan A, MAGE A1, MAGE A3, or MAG...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03716089 · Fujian Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People who have been diagnosed with a stomach tumour called a GIST (a type of gastrointestinal stromal tumour), confirmed by a tissue sample taken during a scope procedure, or confirmed after surgery - People who have provided writte...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03740256 · Baylor College of Medicine Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 December 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with an advanced solid tumour cancer (such as head and neck, salivary gland, lung, breast, bladder, stomach, oesophageal, colorectal, or pancreatic cancer) that has been confirmed by laboratory testing and shows a specific protein called HER2 at a c...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03787056 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 January 2028
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 or older who have been diagnosed with one of the following cancer types, confirmed by laboratory testing of tissue or cell samples: breast, stomach, kidney, prostate, lung (including both main types), liver, colorectal, head and neck, thyroid, pancreatic, ovar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03823144 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People whose overall health and ability to carry out daily activities meets a certain minimum level (a score of 2 or less on a standard medical scale used in cancer care) - People who have a tumour that can be seen and measured, and that needs to be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03825861 · Instituto do Cancer do Estado de São Paulo Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2026
🇧🇷 BR

**Who might be able to join this trial:** - People who have been diagnosed with stomach cancer (specifically a type called adenocarcinoma) that has been confirmed by a tissue sample, where the cancer has grown into or through the stomach wall and/or spread to nearby lymph nodes, but appears to be removable by surgery....

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03900910 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇹🇼 TW

Who might be able to join this trial: - You are between 20 and 60 years old - You are mentally able to understand and agree to the consent form - You are able to communicate with the people running the study Who may not be able to join: - You are currently pregnant - You have one or more serious existing health condit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03941561 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2022
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People who have been confirmed by tissue testing to have primary stomach cancer (adenocarcinoma) at stage II - People who have had surgery that removed all visible cancer (R0 surgery) along with removal of nearby lymph nodes - People...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03961373 · University of Siena Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2023
🇮🇹 IT

**Who might be able to join this trial:** - People aged 18 or older - People with a confirmed diagnosis of primary stomach cancer (stage IIA to IIIC, based on tissue testing), before starting chemotherapy treatment, and who have not had any previous surgery or chemotherapy for this cancer - People whose CT scan shows...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03972956 · Renmin Hospital of Wuhan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 December 2023
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with colorectal cancer, gastric cancer, or a non-cancerous condition that requires surgery. - People who are willing and able to give their informed consent to participate. Who may not be able to join: - People whose other existing health condition...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03978078 · Institut du Cancer de Montpellier - Val d'Aurelle Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed (confirmed by tissue testing) with adenocarcinoma — a specific type of cancer — in one of these locations: colon, rectum, small intestine, pancreas, stomach, bile duct, or oesophagus - People who are about to start the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04022109 · University of Latvia Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2022
🇧🇷 BR🇨🇱 CL🇨🇴 CO🇱🇻 LV🇺🇦 UA

**Who might be able to join this trial:** - People who have been diagnosed with gastric (stomach) cancer (Groups 1 & 2) - People who are currently having or have already had a camera examination of the upper digestive tract (an endoscopy) for medical reasons (Groups 3 & 5) - People aged 40–64 who are considered average...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04024917 · Institut du Cancer de Montpellier - Val d'Aurelle Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇫🇷 FR

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with cancer that has spread to the lining of the abdomen (peritoneal carcinosis) and are waiting for a type of surgery to remove it (cytoreductive surgery) - You scored above 3 on an anxiety or psychological distress scal...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04047953 · Peking University Cancer Hospital & Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2023
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old, male or female. - People whose general health and ability to function meets a minimum standard score (called Karnofsky Performance Status Score ≥70), meaning they are able to carry out normal activity with only minor symptoms (confirm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04090034 · Methodist Health System Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are over 18 years of age - People who have been diagnosed with a neuroendocrine tumour (NET) that started in the stomach, intestines, or pancreas, and whose treating doctor has agreed they should receive a treatment called PRRT (a type of targeted radiation therap...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04107077 · University of Chicago Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with gastric cancer with peritoneal metastases (cancer that has spread to the lining of the abdomen), confirmed by a tissue sample, and/or have cancer cells found in fluid around the abdomen, and who have already completed at least 2 to 4 month...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04147078 · Sichuan University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who have recently received their first diagnosis of stomach cancer, liver cancer, non-small cell lung cancer, or colorectal cancer, and have had surgery or ablation treatment with the goal of fully removing the cancer. - People whose doctors expect them to live for more th...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04191551 · Stanford University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People between the ages of 35 and 84 who are already scheduled for an outpatient endoscopy (a procedure to look inside the digestive tract) - People having that endoscopy for one of these specific reasons: abdominal pain, indigestion, low iron levels in the blood, testing for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04214119 · Johns Hopkins University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 December 2028
🇺🇸 US

Who might be able to join this trial: - People who are having a camera examination of the throat, stomach, and upper digestive tract at Johns Hopkins Hospital between January 2016 and December 2025 - People who are older than 18 years of age - People who are able to swallow a capsule Who may not be able to join: - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04214990 · National Cancer Center, Korea Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 March 2031
🇰🇷 KR

**Who might be able to join this trial:** - Men and women between the ages of 19 and 70 years old - People who have had a procedure (done through a camera scope) to remove a high-grade pre-cancerous growth or early stomach cancer - People whose tissue results after the removal procedure met specific medical guidelines...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04221893 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed (through tissue samples, cell samples, or scans) to have metastatic cancer of the gastrointestinal system, including cancers of the esophagus, stomach, gastroesophageal junction, small intestine, liver, pancreas, bile ducts, colon, rectum, or a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04278222 · Shanghai Changzheng Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2024
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with stomach (gastric) cancer that has spread to other parts of the body (stage IV), confirmed by a tissue sample test - You have not had any previous systemic (whole-body) cancer treatment, OR your cancer came back or spread more than 12 months after...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04282044 · BioEclipse Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2025
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed (confirmed by a tissue sample/biopsy) with one of these specific cancers: triple-negative breast cancer, colon or rectal cancer, liver cancer (hepatocellular carcinoma), bone cancer (osteosarcoma), ovarian cancer, melan...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04282083 · Italian Association Neuroendocrine Tumors Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇮🇹 IT

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have a confirmed diagnosis of a neuroendocrine tumour (NET), either through a tissue sample test or through a specific type of scan (Gallium-68 PET scan) combined with an advanced imaging scan (CT scan or MRI) - People whos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04290806 · iOMEDICO AG Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇩🇪 DE

Who might be able to join this trial: - People who have been diagnosed with stage IV (advanced, spread) cancer of the oesophagus (squamous cell or adenocarcinoma), stomach, or the junction between the stomach and oesophagus, confirmed by a tissue biopsy - People who are planning to start their first round of drug-based...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04295473 · Nanchong Central Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with stomach cancer (specifically a type called adenocarcinoma), confirmed by a tissue test, at stages T1 through T4. - You are generally able to carry out daily activities with little to no limitation (confirm with trial site). - Your liver, kidneys, and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04312633 · CDx Diagnostics Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇺🇸 US

**Who might be able to join this trial:** - You are able to read, understand, and sign the study's consent form - You are 18 years of age or older - You have heartburn or acid reflux and are having a scope procedure (camera down the throat) to check for a condition called Barrett's esophagus, and you will have two spe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04325425 · Centre Hospitalier Universitaire Dijon Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2029
🇫🇷 FR

Who might be able to join this trial: - People diagnosed with a specific type of aggressive, poorly differentiated (Grade 3) neuroendocrine carcinoma, or a mixed tumour where at least 30% is this type, originating from the digestive system, pancreas, or of unknown origin - People whose cancer has spread to other parts...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04329494 · City of Hope Medical Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 5 January 2028
🇺🇸 US

Who might be able to join this trial: - People who have given written informed consent, or whose legal representative has done so on their behalf. - People who have been confirmed by biopsy or tissue testing to have ovarian, uterine, gastric, appendiceal, or colorectal cancer that has spread to the lining of the abdome...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04342910 · Jiangsu HengRui Medicine Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with stomach (gastric) or gastroesophageal junction cancer confirmed by a tissue or cell sample, where the cancer type is adenocarcinoma. - People whose cancer has spread to other parts of the body or has grown in a way that makes surgery not p...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04379596 · AstraZeneca Phase 2 · 14 countries Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇧🇷 BR🇨🇦 CA🇨🇳 CN🇩🇪 DE🇮🇹 IT🇯🇵 JP🇳🇱 NL🇵🇱 PL +6 more

**Who might be able to join this trial:** - Adults aged 18 or older (additional age rules may apply depending on local regulations) - People who have been diagnosed with a stomach, gastroesophageal junction (GEJ), or esophageal cancer (a specific type called adenocarcinoma) that cannot be surgically removed, has sprea...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04421820 · Bold Therapeutics, Inc. Phase 2 · 7 countries Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇨🇦 CA🇩🇪 DE🇮🇪 IE🇮🇹 IT🇰🇷 KR🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People aged 18 years or older - Men, or women who are not pregnant and who agree to follow the contraception requirements set out in the study protocol - People who have a gastrointestinal (digestive system) cancer that has spread to other parts of the body or cannot be remo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04427449 · Shenzhen Geno-Immune Medical Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2029
🇨🇳 CN

**Who might be able to join this trial:** - People who are older than 6 months of age. - People whose tumor tissue has been tested and confirmed to have a specific protein called CD44v6 present, detected through laboratory testing of a tissue or blood sample. - People who are in reasonably good general health (as measu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04447352 · Krankenhaus Nordwest Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2026
🇩🇪 DE

**Who might be able to join this trial:** - People who have been diagnosed through a tissue biopsy with a specific type of stomach or gastroesophageal junction cancer (called adenocarcinoma, diffuse or mixed type) that doctors have assessed as surgically removable, at a certain stage of local growth, with no spread to...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04483076 · Chinese PLA General Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2022
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years old who are not bedridden and are able to carry out daily activities with little or no limitation (confirmed by a standard medical performance scale called ECOG, scored 0 or 1) - People whose stomach cancer has been confirmed by a laboratory tissue...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04485013 · Tizona Therapeutics, Inc Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with advanced or metastatic cancer through a tissue sample test (currently, only colorectal cancer patients are being enrolled). - People who are 18 years of age or older and are willing and able to give their consent to participate. - People who ha...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04512716 · Memorial Sloan Kettering Cancer Center Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with diffuse large B-cell lymphoma (a type of aggressive blood cancer) or B-cell acute lymphoblastic leukemia (another blood cancer), including certain related subtypes, where the disease has come back or has not responded to previous treatment...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT04519151 · Sheba Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2023
🇮🇱 IL

**Who might be able to join this trial:** - Women aged 18 or older who have been confirmed by laboratory testing to have a specific type of ovarian, fallopian tube, or peritoneal cancer (not the low-grade or mucinous types) - Women who are not pregnant, not breastfeeding, and either cannot become pregnant or agree to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04547725 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 16 March 2026
🇹🇼 TW

**Who might be able to join this trial:** - People aged between 20 and 75 years old. - People whose blood test results show healthy enough levels of white blood cells, infection-fighting cells (neutrophils), and platelets (cells that help blood clot). - People whose blood test results show that their kidneys are worki...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04557969 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2040
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with, or are suspected of having, a type of tumour called a GIST (gastrointestinal stromal tumour), either confirmed by tissue testing or based on clinical findings. If tissue is available from a previous biopsy, that will be reviewed; a new bio...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04560036 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇦 CA

Who might be able to join this trial: - People aged 18 years or older - People diagnosed with gastro-oesophageal cancer (a type of cancer called adenocarcinoma) that has spread to other parts of the body, either as a new diagnosis or developed from a previous condition - People whose kidneys are functioning well enough...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04595929 · St. Petersburg State Pavlov Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 October 2021
🇷🇺 RU

**Who might be able to join this trial:** - You have been diagnosed with stomach cancer (specifically a type called adenocarcinoma) that has been confirmed by a tissue sample, and doctors believe it can be surgically removed. - Your cancer is at a stage where it has grown into or through the stomach wall (but has not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04597294 · Jagiellonian University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2026
🇵🇱 PL

**Who might be able to join this trial:** - People who have been diagnosed with stomach (gastric) cancer, confirmed by laboratory testing of a tissue sample. - People aged between 18 and 75 years old. - People whose stomach cancer has reached an advanced stage that has spread into or beyond the stomach wall, with or w...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04609592 · Stanford University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have a type of tumour called a gastroenteropancreatic neuroendocrine tumour (NET) that has spread only to the lymph nodes or liver - People whose tumour is classified as a slow-growing type (WHO Grade 1 or 2, with a cell growth rate of 20% or less), which will be...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04613570 · Instituto Portugues de Oncologia, Francisco Gentil, Porto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇵🇹 PT

Who might be able to join this trial: - People who are already scheduled to have an upper digestive tract camera examination (endoscopy) that includes taking small tissue samples from the stomach - People who have a known stomach condition (such as autoimmune gastritis) or a condition that may increase the risk of stom...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04665687 · Samsung Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇰🇷 KR

Who might be able to join this trial: - You are 19 years of age or older - You have been diagnosed with early stomach cancer or a precancerous stomach growth (called gastric adenoma), confirmed by a tissue test - You have leftover tissue samples already stored from a previous biopsy or endoscopic procedure done for you...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04674267 · Dana-Farber Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - People who are 70 years of age or older at the time of their first appointment at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) - People who have been diagnosed with a gastrointestinal cancer, which includes cancers of the esophagus, stomach, pancreas, liver, bile duct,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04710758 · Shanghai Zhongshan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old - Your tumor is located in the middle or upper part of the stomach, and doctors expect it can be fully removed with a type of surgery called total gastrectomy with removal of nearby lymph nodes - Your stomach cancer has been confirmed by a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04734821 · IHU Strasbourg Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 or older - People who have been diagnosed with esophageal or stomach cancer through a biopsy, where the cancer can be surgically removed and has not spread to distant parts of the body - People who are medically cleared for general anesthesia and surgery on the eso...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04778839 · First Affiliated Hospital of Zhejiang University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been confirmed by tissue or cell testing to have advanced solid tumours, where standard cancer treatments have either stopped working or are no longer available. - People aged between 18 and 70 years old (male or female). - People who are expected to live for...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04780256 · Azienda USL Reggio Emilia - IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇮🇹 IT

Who might be able to join this trial: - Adults aged 18 years or older - People who have had a digestive tract tumor removed using an endoscopic procedure (a procedure using a camera and instruments passed through the mouth or bowel, without open surgery), either in the upper or lower part of the digestive system Who m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04787354 · Hallym University Medical Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2024
🇰🇷 KR

**Who might be able to join this trial:** - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed by a tissue or cell sample, and who have had surgery to remove the cancer (a D1 beta or D2 resection) - People whose cancer has been confirmed by pathology a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04798820 · Samsung Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2024
🇰🇷 KR

**Who might be able to join this trial:** - Your stomach cancer has been confirmed by a tissue biopsy and is a specific type called adenocarcinoma. - Your cancer is at an early to intermediate stage (T1N0, T1N1, or T2N0), as determined by a CT scan and surgery findings. - Your tumor is located in the lower or middle pa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04809025 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old - People who have been diagnosed with primary gastric (stomach) adenocarcinoma, confirmed by a tissue biopsy taken within the last 12 months - People who are able to provide written consent to participate - People who are planned to have surgery...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04840056 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
Hong Kong

"Who might be able to join this trial: - Adults aged 18 years or older - People with a confirmed diagnosis of atrophic gastritis (a condition where the stomach lining becomes thin and inflamed) or intestinal metaplasia (a condition where stomach lining cells are replaced by cells similar to those in the intestine), con...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04840264 · Sixth Affiliated Hospital, Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People whose general health and ability to carry out daily activities meets a certain level (confirm with trial site) - People who have been diagnosed through lab testing with a specific type of stomach or oesophageal-stomach junctio...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04842916 · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. I... Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 22 May 2027
🇫🇷 FR🇬🇷 GR🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with stomach cancer or cancer where the stomach meets the food pipe (oesophagus), confirmed by a tissue biopsy, and your cancer may be removable by surgery - You are currently being treated with standard chemotherapy drugs (such as 5-Fluorouracil or Ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04843215 · Tianjin Medical University Cancer Institute and Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2023
🇨🇳 CN

**Who might be able to join this trial:** - People who have had a specific type of stomach cancer surgery called a radical resection (a D2, R0 removal with at least 16 lymph nodes examined), involving removal of part or all of the stomach (but not the greater curvature side of the stomach) - People whose overall physi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04850729 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - Your stomach or gastroesophageal junction cancer has been confirmed by a tissue or cell sample (biopsy), is at a specific stage (locally advanced but has not spread to distant parts of the body or nearby organs), and may be removable with surgery. - You are between 18 and 75...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04871412 · Ottawa Hospital Research Institute Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2028
🇨🇦 CA

Who might be able to join this trial: - Adults who are eligible for a full surgical removal of lung, stomach, or esophageal (food pipe) cancer Who may not be able to join: - People diagnosed with small cell cancer, carcinoid tumours, or gastrointestinal stromal tumours (GIST) - People with lung cancer where only a sma...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04890171 · National Cancer Center, Korea Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2028
🇰🇷 KR

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of early stomach cancer called "undifferentiated type," which includes signet ring cell carcinoma, poorly differentiated tubular adenocarcinoma, or poorly cohesive carcinoma — where the tumor is small (2 cm or less), has not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04891016 · Henan Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - Adults between 18 and 70 years old, of any gender - People who have been diagnosed with stomach cancer (a specific type called gastric adenocarcinoma) confirmed by a lab test - People whose cancer has not spread to distant parts of the body, and whose surgical team considers the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04893785 · National Cancer Institute, Naples Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2025
🇮🇹 IT

**Who might be able to join this trial:** - People aged 18 or older. - People who have been diagnosed with a well-differentiated lung or digestive/hormonal system neuroendocrine tumour (a specific type of slow-to-moderate growing tumour, classified as NET G1, G2, or G3) that has continued to grow after at least one pr...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04900818 · I-Mab Biopharma US Limited Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇨🇳 CN🇺🇸 US

**Who might be able to join this trial:** - People with advanced or spreading solid tumours whose cancer has continued to grow despite standard treatments, who have no remaining standard treatment options, or for whom standard treatments are not suitable (Part 1 – single drug treatment) - People with locally advanced,...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04907643 · Cedars-Sinai Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - You have a cancer that started in the bile ducts, colon, liver, pancreas, peritoneum (lining of the abdomen), rectum, small intestine, or stomach, and there are no plans to surgically remove the tumor during the study - Your cancer can be one of several types, including adeno...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04943484 · Niguarda Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2024
🇮🇹 IT

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with stomach cancer (specifically a type called adenocarcinoma) in the upper, middle, or lower part of the stomach, confirmed by a tissue sample (biopsy) before surgery - People whose cancer is at an advanced local stag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04949282 · Sociedad Española de Medicina Nuclear e Imagen Molecular Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2034
🇪🇸 ES

**Who might be able to join this trial:** - Adults aged 18 years or older - People who have been diagnosed with a somatostatin receptor-positive tumour (a specific type of tumour that shows up on certain scans) that has either spread to other parts of the body or cannot be surgically removed, and that has continued to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04949737 · University Hospital Center of Martinique Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2028
Martinique

Who might be able to join this trial: - You must be over 18 years old, have been living in Martinique for at least 6 months, and have been diagnosed with stomach cancer as your main condition - You must have read the information sheet about the study and signed a form agreeing to take part - You must be covered by soci...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04958720 · Fundación Sociedad Española de Oncologia Médica Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2034
🇪🇸 ES

Who might be able to join this trial: - You are 18 years old or older and have been diagnosed with cancer of the esophagus, the area where the esophagus meets the stomach, or the stomach itself (all types of these cancers are included). - Your cancer may or may not have a specific protein marker called erbB2, and you c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04997837 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 21 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are generally able to carry out daily activities with little or no limitation (as measured by a standard health score of 0 or 1) - Your doctors expect you to live for more than 6 months - You have had a specific type of stomach surgery (called D2/R0 resection) that is con...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04999761 · Taiho Pharmaceutical Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2026
🇯🇵 JP

Who might be able to join this trial: - Adults aged 18 or older (or aged 16 or older for one specific group involving a rare cancer called ASPS) who are willing and able to follow the study schedule and procedures - People with a general health status rated as fully active or able to carry out light work (ECOG perform...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05005403 · AbbVie Phase 1 · 6 countries Recruiting
Recruiting Phase 1 Est. completion 1 July 2027
🇨🇦 CA🇮🇱 IL🇯🇵 JP🇰🇷 KR🇹🇼 TW🇺🇸 US

Who might be able to join this trial: - A recent tissue sample (biopsy) from the cancer must be available — either taken within the last 6 months before joining, or from stored tissue — with no cancer treatment given in between. - People whose general health and ability to carry out daily activities is rated as fully a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05010863 · Second Affiliated Hospital of Wenzhou Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2023
🇨🇳 CN

Who might be able to join this trial: **For people with cancer:** - Adults aged 18 or older - People who have been diagnosed with cancer confirmed by a laboratory tissue test (pathology) - People who are able to provide enough tissue samples for testing - People who have not yet received any cancer treatment - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05033392 · Wan He Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 79 years, of any gender - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and food pipe, confirmed through a biopsy taken during a camera examination of the stomach - People whose cancer has been confirmed by imag...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05059444 · Guardant Health, Inc. Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 1 August 2029
🇫🇷 FR🇩🇪 DE🇮🇹 IT🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People who are over 18 years old - People whose cancer treatment is being given with the goal of curing or removing the cancer completely - People who are planning to have regular check-ups to monitor for cancer coming back, as part of their normal care at the enrolling hosp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05078047 · UNICANCER Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 7 March 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who have signed a written consent form before any trial-related procedures take place. - People aged 18 or older. - People with cancer that has spread to other parts of the body (or is locally advanced and not suitable for local treatment), where the cancer type has b...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05108298 · Eastern Cooperative Oncology Group Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 39 years old at the time of signing up - You have been diagnosed with cancer (of any stage) within the last 12 weeks, confirmed by a tissue or cell test - You have already had, are currently receiving, or are planning to receive cancer treatment — such...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05126290 · Abramson Cancer Center at Penn Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇺🇸 US

Who might be able to join this trial: - People aged 18 years or older - People who carry a specific type of change (called a loss-of-function variant) in a gene called CTNNA1, or people who have a close blood relative (such as a parent, sibling, or child) who carries this type of gene change. The gene change includes c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05140746 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 September 2024
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years. - People who have been diagnosed with a specific type of stomach cancer called gastric adenocarcinoma, confirmed by a tissue sample taken during a camera examination of the stomach. - People whose stomach cancer has been assessed as surgi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05172310 · Karolinska University Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2024
🇸🇪 SE

Who might be able to join this trial: - People who are scheduled for surgery to remove a pancreatic, biliary (bile duct), or stomach lesion - People who are scheduled for their first surgery to remove early-stage ovarian cancer, a surgery to remove as much ovarian cancer as possible after initial treatment, or a surger...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05180864 · Amsterdam UMC Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇩🇪 DE🇮🇹 IT🇳🇱 NL🇬🇧 GB

**Who might be able to join this trial:** - People diagnosed with a type of stomach cancer called gastric adenocarcinoma, where the cancer can be surgically removed and has not spread to distant parts of the body (clinical stage T1-4aN0-3M0) - People who are considered fit enough to undergo surgery (based on a standar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05184803 · Asan Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2027
🇰🇷 KR

**Who might be able to join this trial:** - People who have been diagnosed with metastatic stomach cancer (adenocarcinoma type), confirmed by tissue or cell testing. - People whose scans show the cancer has grown into nearby organs, or has spread to distant lymph nodes that meet specific size and appearance criteria o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05187338 · Second Affiliated Hospital of Guangzhou Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 October 2029
🇨🇳 CN

**Who might be able to join this trial:** - A laboratory test (such as a biopsy or cell sample) has confirmed a cancer diagnosis. - The person is aged 18 or older and is expected to live for more than 3 months. - Liver function falls within a specific range, measured by a scoring system called Child-Pugh class A or B...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05196087 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇨🇦 CA

Who might be able to join this trial: - People who have been diagnosed with a solid tumor, confirmed through a tissue sample (biopsy or similar test). - People whose cancer is at an early stage or has not spread far beyond its original location, and who are either planning to have, or have already had, treatment aimed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05208762 · Seagen, a wholly owned subsidiary of Pfizer Phase 1 · 11 countries Recruiting
Recruiting Phase 1 Est. completion 5 January 2028
🇧🇪 BE🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP🇳🇱 NL +3 more

Who might be able to join this trial: - People who have been diagnosed with one of the following cancer types that has spread or cannot be surgically removed: non-small cell lung cancer, head and neck squamous cell carcinoma (but not nasopharyngeal cancer), esophageal squamous cell carcinoma, triple negative breast can...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05248763 · Academia Sinica, Taiwan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇹🇼 TW

Who might be able to join this trial: - People who have been diagnosed with one of the following cancer types: lung cancer, breast cancer, gastric cancer (stomach cancer), pancreatic cancer, or ovarian cancer Who may not be able to join: - People who have a type of cancer not included in the list above (such as cancer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05264896 · Chinese University of Hong Kong Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2024
Hong Kong

**Who might be able to join this trial:** - You have been diagnosed with a locally advanced cancer (adenocarcinoma) of the stomach or the area where the stomach meets the food pipe (esophagogastric junction), and it has not spread to distant parts of the body - Your cancer is considered removable by surgery based on s...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05269381 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2028
🇺🇸 US

Who might be able to join this trial: **All phases — general requirements:** - People who are willing to provide tumour tissue samples as required by the study protocol - People who have measurable or non-measurable cancer that can be tracked (note: tumour areas that have previously been treated with radiation do not...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05291728 · Second Affiliated Hospital of Xi'an Jiaotong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇨🇳 CN

Who might be able to join this trial: - People who live locally and are over 20 years old. - People who have given verbal agreement to take part in the study. Who may not be able to join: - People who have declined to take part in this research project. - People who did not complete the questionnaires or the blood tes...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05297734 · Stanford University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been newly diagnosed with a solid tumor cancer, or whose cancer has come back after previous treatment. - People who are able to understand the study and are willing to give verbal consent to participate. - People who speak English, Spanish, Chinese, or Vietna...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05303714 · Azienda Ospedaliera Universitaria Integrata Verona Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 September 2025
🇮🇹 IT

**Who might be able to join this trial:** - You have stomach cancer that can be removed by surgery, and a keyhole (laparoscopy) procedure has confirmed that either cancer cells are present in the fluid around your abdomen, or the cancer has spread slightly into the abdominal lining but only to a limited degree (a sprea...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05319639 · Fujian Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2024
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with advanced, inoperable stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed by tissue testing as a type called adenocarcinoma. - People whose cancer may or may not have clearly measurable tumours on scans. - People who are gen...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05332002 · Rutgers, The State University of New Jersey Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed through lab testing with a type of cancer called adenocarcinoma that started in the esophagus, the junction between the esophagus and stomach, or the stomach, and has either spread to other parts of the body or cannot be surgically removed. - P...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05344339 · University Medical Center Ho Chi Minh City (UMC) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇻🇳 VN

Who might be able to join this trial: - People who have been diagnosed with gastric cancer (stomach cancer) - People whose cancer has been assessed as suitable for a type of surgery called radical distal gastrectomy, meaning the cancer has not spread to distant parts of the body (confirm with trial site for exact stagi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05349227 · Pack Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** **For people with cancer:** - People who have a primary diagnosis of cancer - People who finished their main cancer treatment within the last year, or who have been diagnosed with cancer that has spread to other parts of the body (metastatic cancer) - People aged 18 years or o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05360069 · Nanchong Central Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with stomach cancer (a specific type called adenocarcinoma), confirmed by a tissue sample, at stages T1 through T4. - People whose general health and activity level is rated as fully active or restricted only in physically strenuous activity (as...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05365581 · Astellas Pharma Global Development, Inc. Phase 1 · 8 countries Recruiting
Recruiting Phase 1 Est. completion 31 May 2028
🇨🇳 CN🇫🇷 FR🇮🇹 IT🇯🇵 JP Puerto Rico🇰🇷 KR🇪🇸 ES🇺🇸 US

Who might be able to join this trial: - People who are considered adults under the laws of the country where they are enrolling. - Women who are confirmed not to be pregnant (by blood test and medical interview), and who either cannot become pregnant or agree to use reliable contraception from the time of signing cons...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05387005 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇹🇼 TW

Who might be able to join this trial: - Adults who are 20 years of age or older - People who have never been screened or treated for H. pylori (a type of stomach bacteria) infection Who may not be able to join: - People who have had surgery to remove all or part of their stomach (gastrectomy) - People who have been di...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05426135 · Union Hospital, Tongji Medical College, Huazhong University of Science... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇳 CN

Who might be able to join this trial: - People who are suspected of having lung cancer or a lung nodule, stomach cancer or a stomach lesion, or colorectal cancer or a colorectal lesion - People who have signed a consent form agreeing to take part in the trial - People who have detailed medical records available, includ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05438459 · Kyushu University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇯🇵 JP

**Who might be able to join this trial:** - People diagnosed with stomach cancer (gastric adenocarcinoma) that has spread to the lining of the abdomen or caused fluid build-up, and cannot be removed by surgery, or people with advanced or returned pancreatic cancer that cannot be removed by surgery - For the Phase I pa...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05450835 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 May 2025
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 75 years old - People whose stomach tumour has been confirmed by a pathology test to be a type called gastric adenocarcinoma (a common form of stomach cancer) - People who are expected to live for more than 1 year - People whose tumour is located at the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05477576 · RayzeBio, Inc. Phase 3 · 8 countries Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇧🇪 BE🇧🇷 BR🇨🇦 CA🇫🇷 FR🇳🇱 NL🇰🇷 KR🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a slow-growing (Grade 1 or 2) neuroendocrine tumour originating in the gut or pancreas that cannot be removed by surgery and has spread, and you are reasonably well enough to carry out daily activities (confirm with trial site) - Your tumour has...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05482516 · Georgetown University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who are able to give signed consent to participate - People who, in the trial team's judgment, are able to follow the study procedures - People who have been diagnosed with one of the following cancers, confirmed by laboratory testing: colorectal canc...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05482893 · Phanes Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who are able to give written consent and follow the study requirements - People whose cancer can be measured using standard imaging criteria (called RECIST v1.1) - People with advanced or metastatic stomach, gastroesophageal junction, biliary tract, o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05483491 · Christian Hinrichs Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - You must be at least 18 years old. - Your cancer must have spread to other parts of the body (metastatic), and at least 10% of your tumor cells must test positive for a protein called KK-LC-1 on a special lab test — the trial is currently focusing on stomach cancer, non-smal...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05494060 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 to 75 years old, of any gender. - People with a good general health and activity level, as measured by a standard scoring tool (score of 0 or 1 on the ECOG scale, meaning fully active or able to carry out light work). - People who have been diagnosed with stom...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05508126 · The First Affiliated Hospital with Nanjing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with gastric cancer (stomach cancer) confirmed by an endoscopy procedure before surgery, and who have had specific pre-surgery scans (a type of CT scan and/or MRI scan). - People who have no medical reasons preventing them from having a CT or MR...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05514769 · Nanchong Central Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with stomach cancer (a type called adenocarcinoma), confirmed by a tissue sample, at stages T1 through T4. - People whose general health and ability to carry out daily activities meets a certain minimum level (rated 0 or 1 on a standard medical...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05536102 · Shanghai General Hospital, Shanghai Jiao Tong University School of Med... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2023
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old. - People whose general health and ability to carry out daily activities meets a minimum threshold on a standard medical scoring scale (confirm with trial site). - People who have been confirmed through tissue or cell testing to have a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05537129 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2024
🇨🇳 CN

**Who might be able to join this trial:** - The cancer has been confirmed through a tissue sample (biopsy) as a specific type of stomach cancer (gastric adenocarcinoma) located in the upper or middle part of the stomach - Age is between 20 and 80 years old - The person is generally well enough to carry out daily activ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05544019 · Schrödinger, Inc. Phase 1 · 8 countries Recruiting
Recruiting Phase 1 Est. completion 1 November 2027
🇫🇷 FR🇮🇹 IT Moldova🇵🇱 PL🇷🇴 RO🇪🇸 ES🇺🇦 UA🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a type of blood cancer called a mature B-cell malignancy, confirmed through a lab test on a tissue or cell sample. - People who have a measurable or detectable amount of disease, based on the standard assessment system for their specific co...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05561504 · Technical University of Munich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇩🇪 DE

Who might be able to join this trial: - Adults aged 18 years or older - People who have given informed consent to participate in the HelicoPTER study - People who have given informed consent for the HEPY biobank (a collection of biological samples for research) Who may not be able to join: - People who do not have the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05561907 · Northwell Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have a cancer in or near the pancreas, bile duct, ampulla, or duodenum, or a stomach cancer that has spread to block part of the digestive tract - You are experiencing at least 2 of these symptoms: vomiting after eating, stomach pain, being unable to eat or drink, or scan...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05618821 · Fujian Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2025
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 75 years old - People who have been diagnosed with remnant gastric cancer (cancer in the remaining part of the stomach after a previous surgery), where the cancer has not spread to distant parts of the body, based on pre-surgery assessments - People who...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05620628 · Jeeyun Lee Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇰🇷 KR

**Who might be able to join this trial:** - People aged 19 years or older with a body weight above 30 kg - People who have been diagnosed with gastric cancer (stomach cancer) that is at an advanced or progressive stage - People whose stomach cancer has continued to grow or spread during or after 1 or 2 rounds of chemo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05620732 · Shenzhen University General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years, of any gender - People who are willing to take part and who have signed (or whose legal guardian has signed) a consent form - People who have been diagnosed with stomach cancer or pancreatic cancer that cannot be surgically removed, has come back...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05636618 · Perspective Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 26 November 2029
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed with a neuroendocrine tumour (NET) or meningioma (a type of brain tumour) and have not previously received a type of radiation treatment called PRRT. - People whose cancer is locally advanced, cannot be surgically removed, or has sp...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05640609 · West China Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have been confirmed by tissue or cell testing to have a specific type of stomach or gastroesophageal junction cancer (adenocarcinoma, including signet ring cell, mucinous, or hepatoid types) - People whose cancer has been assessed by imaging and surgery as unable...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05640830 · Kangbuk Samsung Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇰🇷 KR

**Who might be able to join this trial:** - People who have advanced gastric (stomach) cancer that tests positive for a protein called HER2, confirmed through specific laboratory tests (including tissue staining tests or gene copy number tests), or through a specialised protein analysis method. - People whose stomach...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05642819 · University of Edinburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed with cancer of the food pipe (oesophagus), stomach, pancreas, colon, or rectum, and are scheduled to have surgery to remove it - **OR** you are scheduled for open abdominal surgery for a non-cancerous, non-inflammatory condition (for example, kidney d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05644431 · Centre Leon Berard Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 January 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years of age or older at the time of signing the consent form - You have been diagnosed through a tissue biopsy with a specific type of stomach or stomach-esophagus junction cancer (adenocarcinoma) that has not spread to other parts of the body, is able to be remov...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05652348 · Technische Universität Dresden Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with, or are suspected to have, cancer that has spread to the lining of the abdomen (peritoneal metastasis) from stomach, gastroesophageal junction (where the stomach meets the food pipe), colon, or rectal cancer - During surgery, it is confirmed that...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05671822 · Suzhou Suncadia Biopharmaceuticals Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 to 75, both male and female - People with locally advanced, inoperable, or metastatic stomach cancer or gastroesophageal junction cancer that has been confirmed by a pathology report as adenocarcinoma - People whose cancer tests positive for HER2 expression - F...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05687357 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medic... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with stomach cancer or cancer where the stomach meets the esophagus (called gastroesophageal junction cancer) that has not yet been treated, and the cancer is at a certain stage of local spread but has not traveled to distant parts of the body (based...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05699655 · Fujian Cancer Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 March 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 70 years old. - You have been diagnosed with stomach cancer (specifically a type called gastric adenocarcinoma), confirmed by a tissue sample, and your cancer is locally advanced with a tumor larger than 5cm or a certain spread pattern (confirm with tr...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05701241 · University Hospital, Antwerp Phase 4 · 2 countries Recruiting
Recruiting Phase 4 Est. completion 1 April 2029
🇧🇪 BE🇳🇱 NL

**Who might be able to join this trial:** - People aged 18 or older - People who are willing and able to provide written consent before any study procedures begin - People whose general health and ability to carry out daily activities meets a certain minimum standard (known as ECOG performance status of 2 or below — c...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05713838 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇩🇪 DE

**Who might be able to join this trial:** - The person has signed a written consent form agreeing to take part in the study. - The treating doctor believes the person is willing and able to follow the study plan, including having planned surgery. - The person is 18 years of age or older at the time of signing the cons...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05714124 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

**Who might be able to join this trial:** - You must be 18 years of age or older - You have a liver disease (either starting in the liver or spread to the liver from elsewhere) that cannot be treated with surgery or by burning/freezing the tumors away - You have liver tumors and are being considered for major liver sur...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05715931 · Yu jiren Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part voluntarily and have signed the consent form after being fully informed about the study. - You are between 18 and 80 years old (any gender). - You have been confirmed by a tissue test (biopsy) to have stomach cancer or cancer at the junction of t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05722275 · Chinese Academy of Sciences Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2023
🇨🇳 CN🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with advanced stomach cancer (at a stage of cT3 or higher), confirmed through a tissue sample taken during a camera examination of the stomach, along with a CT scan and/or an internal ultrasound. - People who have had both a CT scan with contras...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05723718 · Medical University of Lublin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇵🇱 PL

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with gastric (stomach) adenocarcinoma or undifferentiated carcinoma confirmed through a tissue sample test - People whose cancer is classified as Stage II or Stage III based on a specific staging system (the 8th edition...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05739045 · Xiangdong Cheng Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have chosen to take part and have signed a consent form - People aged 18 to 75 years old - People who have been confirmed by a pathology test to have stomach (gastric) cancer or cancer at the junction where the stomach meets the oesophagus (gastroesophageal juncti...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05768932 · SillaJen, Inc. Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 24 December 2026
🇰🇷 KR🇺🇸 US

**Who might be able to join this trial:** **For the main cancer arms of the trial (Substudies 1, 2, 3 and Dose Expansion):** - People who have read and signed a consent form showing they understand the study and agree to take part before any study procedures begin. - People aged 18 or older (or 19 or older in some lo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05813015 · Zhejiang University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People whose stomach cancer or cancer at the junction of the stomach and oesophagus has been confirmed by laboratory testing of tissue or cell samples - People who have had major surgery (including removal of nearby lymph nodes, known as D2 dissection) at the trial centre, a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05850130 · GERCOR - Multidisciplinary Oncology Cooperative Group Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇫🇷 FR

**Who might be able to join this trial:** - People who are willing to take part and have signed a written consent form - People aged 18 or older - People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard oncology scale called ECOG PS 0–2 (confirm wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05854368 · Institut Pasteur Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years old or older - You are willing and able to sign a written consent form before any study procedures begin - You are covered by a social insurance/healthcare system - *(For patients with stomach conditions only)* You have been diagnosed with untreated glandular...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05871099 · The Affiliated Hospital of Qingdao University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2030
🇨🇳 CN

**Who might be able to join this trial:** - People who have not previously received chemotherapy, radiation therapy, or any other anti-cancer treatment - People aged between 18 and 80 years old - Men, or women who are not pregnant or breastfeeding - People who have been confirmed by tissue testing to have stomach aden...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05880667 · Fox Chase Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with any type of solid cancer that has spread (metastatic), confirmed through a tissue or cell sample, with at least one tumour in the abdomen or pelvis that has not been treated with radiation, and that can be measured using standard imaging c...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05892289 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 20 and 80 years old - People whose stomach cancer is located in the upper third of the stomach - People who have been confirmed through a stomach scope procedure (before surgery) to have a specific type of stomach cancer called adenocarcinoma - People whos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05894824 · Yonsei University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇰🇷 KR

**Who might be able to join this trial:** - People who are willing and able to provide written consent before any trial activities begin - Men and women aged 19 years or older - People who have been confirmed through tissue or cell testing to have stomach or gastroesophageal junction (the area where the stomach meets...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05918094 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who understand the study, are willing to follow its requirements, and are happy to sign a consent form agreeing to take part. - People aged 18 to 75 years old. - People who have been diagnosed with advanced stomach cancer or cancer of the junction between the stomach...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05927857 · National Health Research Institutes, Taiwan Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇹🇼 TW

**Who might be able to join this trial:** - People who have been diagnosed with stomach cancer (specifically a type called adenocarcinoma) that has spread to other parts of the body, confirmed by a tissue or cell sample. - People who have only received one round of treatment for their cancer, including those whose can...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05930860 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 August 2025
🇮🇹 IT

"Who might be able to join this trial: - You must be over 18 years old. - You have been diagnosed (through a camera examination of the stomach and tissue sample) with an early-stage stomach growth that can be removed using a specific non-surgical procedure called ESD, based on current medical guidelines. - You have a s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05934331 · LaNova Medicines Zhejiang Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and sign a consent form before any procedures begin. - You are between 18 and 80 years old (inclusive). - You are generally able to carry out daily activities with little or no limitation (confirm with trial site regarding specific fitness level...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05938309 · Fujian Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People who have been diagnosed with, or are suspected to have, a type of stomach tumour called a GIST (gastrointestinal stromal tumour), confirmed either before or after surgery through imaging, camera examination, or laboratory anal...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05969860 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with cancer that has been confirmed by a tissue biopsy (or, for liver cancer specifically, by imaging scans alone) - You have one of the many cancer types listed in the trial, including breast, lung, colon, prostate,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05975749 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 20 and 80 years old - You have been confirmed through biopsy or tissue testing to have stomach cancer (specifically a type called adenocarcinoma) at stage II or III - You have had surgery to completely remove the stomach cancer, including removal of nearby lym...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05977998 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older (there is no upper age limit) - People whose general health and ability to carry out daily activities meets a certain minimum level, based on standard medical scoring scales (confirm with trial site) - People who have been diagnosed with a type of canc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05991947 · Zhejiang Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 100 years old. - You are generally able to carry out daily activities with little or no limitation (confirm with trial site). - You have been diagnosed with Stage I, II, or III stomach cancer, confirmed through lab or tissue testing. - You have not yet...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05993234 · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇦🇹 AT🇧🇪 BE🇩🇪 DE🇮🇹 IT🇵🇹 PT

**Who might be able to join this trial:** - Adults aged 18 or older who have a confirmed diagnosis of HER2-positive advanced stomach cancer or cancer at the junction of the stomach and food pipe (gastroesophageal junction), and who have already received a previous treatment containing a medicine called trastuzumab - Pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05997056 · Aadi Bioscience, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 9 May 2025
🇺🇸 US

**Who might be able to join this trial:** - People who have a well-differentiated (slow-growing), locally advanced or spread neuroendocrine tumour (NET) of the digestive tract, lung, or pancreas, and who have received no more than 2 previous treatments (not counting somatostatin analog drugs such as octreotide) - Peop...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06005493 · AstraZeneca Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 16 July 2027
🇨🇳 CN🇫🇷 FR🇯🇵 JP🇳🇱 NL🇰🇷 KR🇹🇼 TW🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older at the time of signing the consent form - You have been confirmed through a tissue test (biopsy) to have a type of cancer called adenocarcinoma, located in the stomach, the junction between the stomach and food pipe, the food pipe (esophagus), or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06006390 · Chongqing Precision Biotech Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People with an advanced, spreading, or returning cancer that has been confirmed by a tissue or cell sample — mainly colorectal (bowel), esophageal (food pipe), stomach, or pancreatic cancer - People whose cancer has continued to grow...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06010862 · Chongqing Precision Biotech Co., Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with an advanced, spreading, or returning cancer (mainly colorectal, esophageal, stomach, or pancreatic cancer) confirmed by a tissue or lab test - Your cancer has continued to grow or you could not tolerate at least tw...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06023758 · Peking University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are able to understand and freely agree to sign a consent form to participate in the study - You are between 18 and 75 years old (inclusive) at the time of signing the consent form - Your cancer has been confirmed by a lab test (from a tissue or cell sample) to be a HER2...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06027242 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2026
🇹🇼 TW

Who might be able to join this trial: - Adults who have stomach cancer and are having surgery to remove part or all of their stomach (gastrectomy) Who may not be able to join: - People who have liver problems or reduced liver function - People who have kidney problems or reduced kidney function - People who are unable...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06028724 · Centro di Riferimento Oncologico - Aviano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2030
🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years of age or older - You are able to understand, agree to, and sign the official consent form before any study procedures begin - You are willing and able to attend scheduled visits, follow the treatment plan, and complete any required tests or procedures - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06028737 · Ukrainian Society of Clinical Oncology Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 25 April 2027
🇱🇹 LT🇺🇦 UA

**Who might be able to join this trial:** - People diagnosed with stomach (gastric) cancer or cancer at the junction where the esophagus meets the stomach (a specific type called Siewert type 2 or 3), confirmed by a tissue sample (biopsy) - People whose cancer has reached a certain stage of spread within or near the s...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06035250 · Chinese Academy of Sciences Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 31 August 2024
🇨🇳 CN🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with advanced stomach (gastric) cancer, confirmed by a laboratory test of tissue, and staged according to standard American cancer staging guidelines - You have not received any cancer treatments (such as chemotherapy...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06038578 · Toray Industries, Inc Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 30 June 2026
🇯🇵 JP🇰🇷 KR🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed (confirmed by laboratory testing of tissue or cells) with stomach cancer or cancer of the gastroesophageal junction (the area where the stomach meets the food pipe) that has spread to other parts of the body, or that cannot be removed by surger...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06040801 · Chang Gung Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇹🇼 TW

Who might be able to join this trial: - People aged 65 or older who have been diagnosed with stomach, bile duct/gallbladder, or pancreatic cancer that has spread or cannot be surgically removed - People who are willing and able to sign a consent form agreeing to take part in the study - People whose doctors estimate th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06042998 · The Affiliated Hospital of Qingdao University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old, male or female - People whose stomach cancer has been confirmed by biopsy as a specific type of stomach gland cancer (such as papillary, tubular, mucinous, signet ring cell, or poorly differentiated adenocarcinoma) - People whose cancer was st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06043466 · Chongqing Precision Biotech Co., Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with an advanced solid tumor (confirmed by a tissue or lab test) that is one of the following cancer types: colorectal cancer, esophageal cancer, stomach cancer, pancreatic cancer, non-small cell lung cancer, breast...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06054906 · Huashan Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have signed a written consent form to participate - Adults aged 18 or older - People who have been confirmed by tissue testing to have stomach (gastric) adenocarcinoma, where the cancer is locally advanced (spread to nearby tissue or lymph nodes but not to distant...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06055387 · Chang Gung Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇹🇼 TW

Who might be able to join this trial: - People aged 65 or older who have been diagnosed with locally advanced stomach cancer (stage II or stage III) and are preparing to have surgery to remove the cancer. - People who are planned to receive chemotherapy after surgery, starting within 4 to 8 weeks of the operation, whet...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06055439 · Chimeric Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2026
🇺🇸 US

**Who might be able to join this trial:** - Participants (or their legal representative) must be willing and able to give signed consent to take part in the study. - A confirmed tissue diagnosis of one of the following digestive system cancers is required: stomach cancer (gastric adenocarcinoma), colon or rectal cance...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06059495 · GERCOR - Multidisciplinary Oncology Cooperative Group Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2028
🇫🇷 FR

**Who might be able to join this trial:** - People who are able to give written, signed, and dated consent to take part - People who have a good general performance level (able to carry out normal daily activities with little or no limitation, rated 0 or 1 on a standard medical scale) - People aged 18 to 75 years old;...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06065371 · Henry Ford Health System Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older, able to understand the study information, and can give written consent to participate - You have been diagnosed with a type of cancer called metastatic adenocarcinoma that started in the digestive system (such as the stomach/esophagus juncti...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06071507 · IRCCS San Raffaele Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇫🇷 FR🇮🇹 IT🇵🇹 PT Turkey (Türkiye)

**Who might be able to join this trial:** - People who have been diagnosed with pancreatic cancer confirmed by a tissue or cell sample (biopsy or similar test) - People who were diagnosed with pancreatic cancer no more than 6 months ago and are being considered for active treatment - People who have a blockage in their...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06075199 · Seoul National University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2033
🇰🇷 KR

Who might be able to join this trial: - You are a patient who visits Seoul National University Hospital - You have previously been diagnosed with a stomach condition called intestinal metaplasia (a change in the cells lining the stomach) based on a visual examination Who may not be able to join: - You have previously...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06078930 · Zhejiang Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇨🇳 CN

**Who might be able to join this trial:** **For people with gastric (stomach) cancer:** - People aged between 18 and 90 years old - People whose stomach cancer has been confirmed through laboratory testing of tissue or cell samples - People who have not previously received any cancer treatments such as chemotherapy, r...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06081647 · RenJi Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 60 years of age - People who are scheduled to have a gastroscopy (camera examination of the stomach) and/or a colonoscopy (camera examination of the large bowel) - People who have signed the consent form agreeing to take part - People assessed as being...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06085755 · Jeeyun Lee Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇰🇷 KR

**Who might be able to join this trial:** - People aged 19 years or older - People who have been diagnosed with advanced or metastatic stomach cancer or cancer of the junction between the stomach and oesophagus (confirmed by a tissue test), with at least one tumour that can be measured on a scan - People whose cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06091423 · Xiaofeng Chen Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 25 November 2025
🇨🇳 CN

Who might be able to join this trial: - Adults between 18 and 75 years of age - People who are able to understand the study details and are willing to sign a consent form - People who have been confirmed by tissue or cell testing to have HER2-negative or unknown HER2 status stomach, esophageal, or stomach-esophageal ju...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06102759 · Tianjin Medical University Cancer Institute and Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older - People whose physical fitness is rated as good (a performance score of 0–1 on a standard medical scale), and this rating has been stable for at least 7 days - People who have been confirmed through a tissue biopsy to have stomach cancer or cancer of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06102772 · Tianjin Medical University Cancer Institute and Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older - You are in generally good physical condition and able to carry out daily activities with little or no limitation (confirm with trial site regarding specific fitness scoring) - You have been diagnosed through a tissue biopsy with stomach can...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06102785 · Tianjin Medical University Cancer Institute and Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older. - People whose general health and ability to carry out daily activities is rated at a good level (ECOG score of 0 or 1), and has been stable for at least 7 days. - People who have been diagnosed through a tissue biopsy with stomach cancer or cancer a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06105515 · Region Stockholm Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇸🇪 SE

Who might be able to join this trial: - You have been diagnosed with stomach cancer that has grown into the stomach wall or nearby tissues but has not spread to the lymph nodes or other parts of the body - Your stomach tumor falls into a specific shape/growth pattern category (called Borrmann type 1-2) and is smaller t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06121700 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus (excluding a specific type called Siewert type I), confirmed by a tissue sample test. - People whose cancer has spread (metastasised) only in a limited way — either to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06123494 · Jiangsu HengRui Medicine Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old, of any gender - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed by a tissue or cell sample, that cannot be surgically removed and has either spread locally or to other parts...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06126406 · Chongqing Precision Biotech Co., Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with an advanced, spread, or returning cancer (mainly colorectal, esophageal, stomach, or pancreatic cancer) confirmed by a tissue or lab test - Your cancer has continued to grow or you could not tolerate at least two r...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06128252 · Tang-Du Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (any gender) - You have been diagnosed through a lab test (biopsy) with stomach cancer or cancer at the junction of the stomach and food pipe (gastroesophageal junction), at a specific intermediate-to-advanced stage (stage II or III, meani...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06128551 · Revolution Medicines, Inc. Phase 2 · 7 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL Puerto Rico🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You must be at least 18 years old - Your cancer must have been confirmed by a tissue test (biopsy) and have a specific genetic change called a KRAS G12C mutation, and it must be advanced or spread to other parts of the body with no curative treatment available - For the early...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06131840 · Seagen, a wholly owned subsidiary of Pfizer Phase 1 · 9 countries Recruiting
Recruiting Phase 1 Est. completion 12 September 2029
🇨🇦 CA🇨🇳 CN🇫🇷 FR🇯🇵 JP🇳🇱 NL🇪🇸 ES🇸🇪 SE🇬🇧 GB +1 more

**Who might be able to join this trial:** - People who have been diagnosed with a solid tumour cancer that has spread or cannot be surgically removed, confirmed by laboratory testing of tumour tissue or cells, and who have run out of standard treatment options (Parts A and B). - In Part A (dose escalation), the cancer...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06138223 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2028
🇳🇱 NL

Who might be able to join this trial: - People diagnosed with incurable adenocarcinoma (a type of cancer) of the esophagus or stomach that cannot be cured. - People whose cancer has come back after treatment that was aimed at curing it, or whose cancer had already spread or could not be surgically removed at the time o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06155318 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 May 2029
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with a type of tumour called a gastroenteropancreatic neuroendocrine tumour (GEP-NET), confirmed by tissue sample or imaging, and who have been referred for a specific type of scan called a 68Ga-DOTATOC PET scan. - People who are 18 years of age or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06155383 · RemeGen Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part and have signed a consent form agreeing to participate - Adults aged 18 or older, of any gender - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and food pipe (gastroesophageal junction adenocar...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06157996 · Nanfang Hospital, Southern Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part voluntarily, sign a consent form, and follow the study requirements - Adults aged 18 or older, of any gender - People who have been confirmed by tissue or cell testing to have advanced (stage IV) stomach cancer or cancer at the junction of the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06158919 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 November 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have fully understood the study and have signed a consent form agreeing to take part voluntarily - People aged 18 to 80 years old (inclusive), of any gender - People who have been confirmed by pathology or tissue testing to have advanced or metastatic stomach canc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06177041 · FutureGen Biopharmaceutical (Beijing) Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 11 January 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent to participate in the study. - People who have a confirmed diagnosis of advanced stomach or gastroesophageal junction (stomach-oesophagus junction) cancer that cannot be surgically removed, or that has spread to other parts of the body,...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06196697 · Harbin Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years old at the time of signing the consent form - People with stomach cancer (gastric cancer) or cancer at the junction of the stomach and oesophagus that cannot be removed by surgery and has either spread to nearby areas or to other parts of the b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06199895 · Liu Huang Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed (through a tissue or cell sample) with advanced pancreatic cancer, bile duct cancer (cholangiocarcinoma), lung cancer, stomach cancer, esophageal cancer, or breast cancer, and have at least one measurable area of can...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06202105 · University Medical Center Ho Chi Minh City (UMC) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 August 2032
🇻🇳 VN

**Who might be able to join this trial:** - You have been diagnosed with stomach cancer (specifically a type called adenocarcinoma), confirmed by a camera procedure looking inside your stomach (endoscopy) - You are between 18 and 80 years old - Your cancer requires a full removal of the stomach as part of your treatmen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06203327 · Shanghai Jiao Tong University School of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2034
🇨🇳 CN

Who might be able to join this trial: - People who are willing and able to take part in the study and agree to sign a consent form - People who have had stomach tissue samples (biopsies) collected following a standard medical guideline called the updated Sydney system Who may not be able to join: - People who are youn...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06221748 · RemeGen Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have voluntarily agreed to take part and have signed a consent form - People aged between 18 and 75 years old (inclusive) - People whose doctors expect them to live for at least 12 weeks - People with a good general physical functioning level, rated 0 or 1 on a st...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06222645 · Saint Petersburg State University, Russia Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 30 April 2026
🇨🇳 CN🇷🇺 RU

Who might be able to join this trial: - People who are 18 years of age or older - People who are scheduled to have a planned (non-emergency) surgery to remove part of the digestive system, where the remaining sections will be reconnected - People who are able to understand the study and sign a written consent form Who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06227728 · Gene Solutions Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇻🇳 VN

Who might be able to join this trial: - Adults aged 18 years or older, of any gender - People who have been diagnosed with stage IV cancer (such as lung, colorectal, breast, liver, or stomach cancer) and whose doctor has recommended treatment with immune checkpoint inhibitor (immunotherapy) drugs, either as a first or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06232434 · Research Institute for Physical Chemical Problems of the Belarusian St... Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2025
Belarus

**Who might be able to join this trial:** - You have stomach cancer (that has not spread to the food pipe/esophagus) that has spread to the lining of the abdomen (peritoneum), at various stages of spread to lymph nodes. - Doctors expect you to live for at least 6 months. - You are generally able to carry out daily acti...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06250036 · Royal Marsden NHS Foundation Trust Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 March 2027
🇬🇧 GB

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed by a tissue biopsy - People whose cancer has a specific genetic feature called MMR deficiency or microsatellite instability-high (M...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06253611 · GERCOR - Multidisciplinary Oncology Cooperative Group Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who have signed a dated written consent form before any study-related procedures begin - People who are willing and able to attend scheduled visits, follow the treatment plan, and complete required tests - People diagnosed with inoperable, advanced, or metastatic stom...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06253650 · Gruppo Oncologico del Nord-Ovest Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇮🇹 IT

**Who might be able to join this trial:** - People who are 18 years of age or older. - People who have had surgery to remove stomach cancer, cancer at the junction of the stomach and food pipe (gastroesophageal junction), or adenocarcinoma of the food pipe (esophagus), after completing pre-operative chemotherapy with...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06253871 · Iambic Therapeutics, Inc Phase 1 · 8 countries Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇫🇷 FR🇮🇪 IE🇮🇹 IT🇳🇱 NL🇰🇷 KR🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have a cancer that has come back or stopped responding to treatment, and your cancer has a specific change (alteration) in a protein called HER2 - Your cancer has continued to grow after your last treatment, or you were unable to tolerat...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06256705 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 March 2028
🇫🇷 FR

**Who might be able to join this trial:** - Your medical team (MDT) has decided to refer you for a type of radiation treatment called PRRT - You have been diagnosed with a neuroendocrine tumour (NET) originating from the gut, pancreas, or stomach (or a NET of unknown origin but thought to come from that area), confirm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06263088 · Case Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older. - People who identify as Black and have been newly diagnosed with a gastrointestinal (digestive system) cancer, at any stage. The cancer types that may be eligible include cancers of the anus, rectum, colon, small bowel, appendix, liver or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06266299 · Kyowa Kirin Co., Ltd. Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 March 2029
🇯🇵 JP🇺🇸 US

Who might be able to join this trial: - People who are 18 years old or older at the time of giving consent to participate - People whose cancer can be measured using standard imaging methods (a system called RECIST v1.1) - People who are relatively well and able to carry out daily activities, based on a standard health...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06275204 · University of Latvia Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇭🇷 HR🇮🇪 IE🇱🇻 LV🇵🇱 PL🇷🇴 RO🇸🇮 SI

Who might be able to join this trial: - You are generally between 30 and 34 years old. Who may not be able to join: - You have a mental or developmental condition that makes it difficult to fully understand and agree to take part in the study (this is assessed by the research team or your own doctor). - You have previ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06289374 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇬🇧 GB

Who might be able to join this trial: - People who are between 18 and 90 years of age at the time of joining - People who have been diagnosed with adenocarcinoma (a specific type of cancer) of the stomach or oesophagus (food pipe), confirmed by biopsy, and who have already been enrolled in a related study called BIORES...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06293898 · SystImmune Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 December 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older - People whose doctors estimate they have a life expectancy of at least 3 months - People who have been diagnosed with a locally advanced or spreading solid tumour that tests positive for a protein called HER2 (detected by specific lab tests), where s...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06296706 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years old (on the day they sign the consent form) - People who have been diagnosed with stomach cancer or cancer of the junction between the stomach and oesophagus, confirmed by a tissue or cell test - People whose stomach or gastroesophageal junction cancer...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06300879 · Huashan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People whose cancer has been confirmed by a laboratory test to be a type called adenocarcinoma - People whose cancer is located in the upper part of the stomach or at the junction where the stomach meets the food pipe (a specific type...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06306755 · Peking University Cancer Hospital & Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who permanently live in the target villages in Xun County, Henan Province, China - People who are between 50 and 69 years old at the time of enrollment - People who are willing to take part and agree to give their informed consent **Who may not be able to join:** - Pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06313567 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 10 March 2029
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 80 years old - People who have been confirmed by laboratory testing to have a specific type of stomach cancer called primary adenocarcinoma, at stage III - People who have had a type of stomach surgery (gastrectomy) where all visible cancer was rem...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06327386 · Daping Hospital and the Research Institute of Surgery of the Third Mil... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with stomach cancer (specifically a type called gastric adenocarcinoma) that has reached a certain stage of spread, meaning it has grown into the stomach wall and/or spread to nearby lymph nodes - You had an MRI scan with contrast dye to assess your ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06337760 · European Institute of Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

Who might be able to join this trial: - People who were first diagnosed with their cancer between the ages of 18 and 39. - People who have a carcinoma (a type of cancer) originating from the esophagus, stomach, pancreas, bile ducts, liver, small bowel, colon, rectum, anus, or from an unknown primary site — any tissue s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06338683 · Qinghai Red Cross Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 20 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 years or older - People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard cancer performance scale (scores 0–3) - People diagnosed with stage III or IV stomach cancer, esophageal cancer, liver...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06341595 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand and sign a consent form agreeing to take part - People aged 18 to 75 years old, of any gender - People who have been confirmed through a tissue biopsy to have stomach cancer or cancer of the junction between the stomach and food pipe (gastro...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06346080 · KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇧🇪 BE

Who might be able to join this trial: - You are between 18 and 75 years old - You have access to a computer or smartphone - You can read and understand one of the following languages: English, French, Dutch, Spanish, German, Chinese, or Japanese Who may not be able to join: - You are younger than 18 or older than 75 y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06349044 · Zhejiang Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been confirmed by tissue testing to have a malignant (cancerous) tumour of the digestive tract — this includes a specific type of stomach or stomach-junction cancer (HER-2 negative), liver cancer, bile duct or gallbladder cancer, or colorectal cancer. - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06356467 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇹 IT

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with a well-differentiated gastroenteropancreatic neuroendocrine neoplasm (a type of slow-growing tumour in the gut or pancreas) that is either localised (but not suitable for surgery) or has spread locally or to other...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06364410 · National Cancer Institute (NCI) Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 8 July 2027
🇺🇸 US

Who might be able to join this trial: - People who have a solid tumour (dose escalation phase) or stomach/gastroesophageal junction cancer (dose expansion phase) that is advanced, cannot be surgically removed, or has spread, and has continued to grow after at least one previous treatment. - People whose tumour tests po...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06383559 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older - People who have been diagnosed with advanced or metastatic stomach cancer confirmed by a tissue biopsy, where the cancer does not show liver-like cell features, tests negative for a protein called HER-2, and has a blood protein level (AFP) of 20 ng/ml or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06389448 · Huazhong University of Science and Technology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇨🇳 CN

Who might be able to join this trial: - You are between 18 and 75 years old - You have been diagnosed through a stomach biopsy (tissue sample) with low-grade abnormal cells, high-grade abnormal cells, or early-stage stomach cancer, and the affected area has clear edges that can be seen during a camera examination of th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06395519 · 858 Therapeutics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with an advanced solid tumour cancer (one that has spread, cannot be removed by surgery, or has come back) that is not a brain tumour that started in the brain or spinal cord - Your cancer has gotten worse during or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06395935 · Gyeongsang National University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2025
🇰🇷 KR

Who might be able to join this trial: - Adults between 19 and 75 years of age who have had surgery to remove all or part of the stomach (called a radical gastrectomy) Who may not be able to join: - People who are unable to attend regular follow-up appointments - People who have difficulty with communication - People w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06399757 · Apollo Therapeutics Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years old or older - For the main Phase 1 part of the trial, you must have been diagnosed with one of these cancers that has spread or cannot be removed by surgery: colorectal cancer, bile duct cancer (cholangiocarcinoma), or appendix cancer (appendiceal adeno...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06402695 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with a neuroendocrine tumour (NET) of the gut, pancreas, or lungs, confirmed through a tissue biopsy or sample analysis. - People aged 18 years or older. - People whose scans show a tumour that can be surgically removed, is locally advanced, or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06405113 · Changzhou No.2 People's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years old (including those who are exactly 18 or 80) - People who understand what the study involves and are willing to sign a consent form - People who have been confirmed by tissue or cell testing to have advanced or spreading stomach cancer or cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06408220 · City of Hope Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 October 2029
🇺🇸 US

**Who might be able to join this trial:** - You have agreed to take part and signed a consent form (or a legal representative has done so on your behalf) - You are between 40 and 80 years old - You identify as Asian, Hispanic, or Black American - You are willing to give blood samples and have a camera procedure to look...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06413212 · Liu Huang Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 to 75 years old, of any gender - People who have been assessed as not being at significant nutritional risk, based on a standard screening tool called NRS2002 (scoring less than 3) - People whose cancer has been confirmed by biopsy and cannot be surgically removed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06414733 · Pravin T.P Kaumaya Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with metastatic or inoperable breast cancer or gastrointestinal cancer, confirmed by tissue biopsy. - People whose cancer has continued to grow or spread after at least one standard treatment. - People with pancreatic or esophageal cancer who h...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06415669 · The First Affiliated Hospital of Xiamen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 19 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old, of any gender. - People with a good general health and activity level, rated 0 or 1 on a standard performance scale used by doctors (called ECOG score). - People who have been diagnosed with stomach cancer or cancer at the junction of the stom...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06417892 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have fully understood the study and have voluntarily signed a consent form - People aged 18 or older - People who have been diagnosed through laboratory testing with advanced stomach cancer or cancer at the junction of the stomach and oesophagus, and who have alre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06421324 · Fundación para la Investigación del Hospital Clínico de Valencia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇪🇸 ES

Who might be able to join this trial: - You are 18 years old or older and have been diagnosed with gastric intestinal metaplasia (a change in the stomach lining) or have had, or currently have, an H. pylori infection (a type of stomach bacteria) - You are already scheduled to have a stomach camera examination (gastrosc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06422403 · National University Hospital, Singapore Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 March 2029
🇸🇬 SG

**Who might be able to join this trial:** - You are willing and able to give your consent to take part before any study procedures begin - You fall into one of three groups: (A) you have advanced or spreading stomach, gastroesophageal junction, or esophageal cancer of a specific type (HER2-negative, PDL1 CPS ≥5%) that...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06427941 · BeOne Medicines Phase 1 · 9 countries Recruiting
Recruiting Phase 1 Est. completion 30 May 2028
🇧🇷 BR🇨🇳 CN🇫🇷 FR🇮🇹 IT🇯🇵 JP🇳🇿 NZ Puerto Rico🇰🇷 KR +1 more

**Who might be able to join this trial:** - People who have one of the following cancers that cannot be surgically removed, has spread to other parts of the body, or is locally advanced: liver cancer (hepatocellular carcinoma) at a certain stage or that has not responded to other local treatments; stomach cancer that...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06429891 · Hua Zhu Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older who have a good level of physical functioning (rated 0 or 1 on a standard activity scale used by doctors) - People who have been diagnosed with a solid tumour, confirmed through laboratory analysis of tissue - People who have at least one tumour that c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06431100 · Beijing Geekgene Technology Co., LTD Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old, of any gender - People with advanced cancer that cannot be cured — including stomach cancer, esophageal cancer, cervical cancer, triple-negative breast cancer, non-small cell lung cancer, or other cancers — where standard treatments have stopp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06441331 · ITM Solucin GmbH Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 1 June 2028
🇫🇷 FR🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - Children and young people aged 2 years old up to (but not including) 18 years old - People who have a confirmed diagnosis of a tumour that tests positive for a specific protein called the somatostatin receptor (SSTR) - People whose tumour has come back or has stopped respond...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06451211 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2024
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with stomach cancer (specifically a type called gastric adenocarcinoma) confirmed by a tissue sample, at a stage that has not spread to distant parts of the body - You are male or female, between 18 and 70 years old - A camera test of your stomach (ga...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06461910 · Zekuan Xu Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 January 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years who have been diagnosed with stomach (gastric) cancer or cancer at the junction of the stomach and oesophagus (gastroesophageal junction cancer). - People whose cancer has been confirmed by endoscopy and tissue testing (pathology) to be a specific...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06464978 · Nanchong Central Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 85 years old. - People who have been diagnosed with stomach cancer through laboratory testing, and whose condition is suitable for a surgery that removes part of the stomach. - People who are fully active or able to carry out light work, with minimal or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06466902 · Azienda Ospedaliero-Universitaria di Parma Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
🇮🇹 IT

Who might be able to join this trial: - People who are having minimally invasive surgery (laparoscopic or robotic) aimed at curing stomach cancer (gastric adenocarcinoma) - People who are having surgery either as their first treatment or after receiving chemotherapy before surgery - People who are having either a full...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06468280 · Shanghai Zhongshan Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 79 years old, either male or female. - People who have been diagnosed through laboratory testing with stomach cancer (gastric adenocarcinoma) or cancer at the junction of the stomach and food pipe (gastroesophageal junction adenocarcinoma, specifically Siew...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06475170 · Northern Jiangsu People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (male or female) - A tissue sample (biopsy) taken before surgery has confirmed you have stomach cancer located in the upper third of the stomach (including where the stomach meets the food pipe) - Your cancer is at an early stage (Stage Ia...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06485271 · Changzhi People's Hospital Affiliated to Changzhi Medical College Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇳 CN

Who might be able to join this trial: - People aged 18 or older, of any gender - People who have been diagnosed with advanced stomach cancer confirmed by a tissue or cell sample, including those whose cancer came back or got worse more than 6 months after completing follow-up cancer treatment - People who have at least...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06487221 · Ryan H. Moy, MD, PhD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a specific type of stomach or gastroesophageal junction cancer (diffuse type, poorly cohesive, signet ring cell, or mixed type), confirmed by a tissue or cell sample — or people with certain genetic mutations (CDH1 and/or RHOA) regardless of ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06487429 · Union Hospital, Tongji Medical College, Huazhong University of Science... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily, are able to sign a consent form, and are likely to follow the study requirements - People aged 18 to 75 years old at the time of signing the consent form, of any gender - People who have been diagnosed with stomach cancer or c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06490159 · City of Hope Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 June 2028
🇯🇵 JP

Who might be able to join this trial: - People who have been diagnosed with stomach cancer (specifically a type called adenocarcinoma) that cannot be removed by surgery or has come back after treatment. - People who are 20 years of age or older. - People whose general health and ability to carry out daily activities fa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06495645 · The University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
Hong Kong

Who might be able to join this trial: - You are 40 years old or older - You are already scheduled to have an upper endoscopy (a procedure where a doctor uses a thin, flexible tube with a camera to look inside your throat and stomach) Who may not be able to join: - You are currently pregnant - You are unable to sign a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06500052 · Sichuan Baili Pharmaceutical Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to sign a consent form and agree to follow the study rules - You are between 18 and 75 years old (for the first part of the study), or 18 or older (for the second part) - You have been diagnosed with a locally advanced or spreading solid tumour (such as a dig...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06504732 · SUNHO(China)BioPharmaceutical CO., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old (any gender) - People in a specific group (Cohort 1, Phase II) who have been diagnosed with advanced or spread-out stomach cancer (including cancer at the junction of the stomach and food pipe) confirmed by a tissue test, where surgery or local...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06506292 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have chosen to take part voluntarily and have signed a consent form - People aged 18 to 75 years old, of any gender - People who have been diagnosed with stomach cancer (adenocarcinoma) or cancer at the junction of the stomach and food pipe, confirmed by a tissue...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06506825 · Qun Zhao Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with gastric cancer (stomach cancer) Who may not be able to join: - There are no listed exclusion criteria for this trial Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06508307 · GONGCHU Biotechnology Co., Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who fully understand the trial's purpose, risks, and methods, and who are willing to sign a consent form before any procedures begin. - Men or women between the ages of 18 and 75. - People who have been diagnosed with an advanced solid tumour (such as colorectal, lung...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06510010 · Sixth Affiliated Hospital, Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been fully informed about the study and have signed a consent form agreeing to take part - People whose stomach or stomach-oesophagus junction cancer has been confirmed by a stomach camera (gastroscopy) and biopsy as a locally advanced type called adenocarcin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06519500 · Regina Elena Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 March 2026
🇮🇹 IT

Who might be able to join this trial: - Adults aged 18 or older. - People who have been diagnosed with a type of tumour called a gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN), confirmed either through a tissue sample examination or through a specific type of scan called a 68Ga-PET-CT scan. - People for whom...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06519591 · Ruijin Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with stomach (gastric) cancer of a specific type called adenocarcinoma, where lab tests show the tumour is HER2-negative, and who have not had surgery to remove the primary tumour or any spread of the cancer - People whose stomach cancer has sp...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06521541 · The Affiliated Hospital of Qingdao University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇨🇳 CN

Who might be able to join this trial: - You must be 18 years of age or older - You must be well enough to carry out some daily activities (your doctor will assess this using a standard scale called ECOG, scoring 0, 1, or 2) - Your stomach cancer must have been confirmed by a tissue sample (biopsy) taken during an endos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06532799 · Essen Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 16 and 90 years old - You have been diagnosed with cancer (primary, returned, or spread to other parts of the body) confirmed by a tissue test - Your doctors expect you to live for more than 3 months - You are well enough to carry out some daily activities (a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06534814 · Hebei Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with gastric cancer (stomach cancer), whether newly diagnosed or returning after previous treatment - People whose imaging scans or pathology reports show possible or confirmed spread of cancer to the lymph nodes - People aged 18 years or older...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06543108 · Hunan Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 years or older - People who have been diagnosed with stomach (gastric) cancer - People who are able to have both FAPI PET/CT and FDG PET/CT scans (two types of medical imaging) within one week of each other - People who are able to have a blood test to check tu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06544265 · Verismo Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older. - People who have a confirmed laboratory diagnosis of a type of blood cancer called B-cell non-Hodgkin lymphoma (B-NHL). - People who have previously received a treatment called CAR T-cell therapy, or who were unable or unwilling to receive it. - Pe...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06550063 · St. James's Hospital, Ireland Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2025
🇮🇪 IE

Who might be able to join this trial: - You have been diagnosed with a type of cancer called esophagogastric adenocarcinoma (a cancer of the oesophagus or stomach) for the first time, diagnosed between the year 2000 and April 2024, at any stage of the disease. - Your tumour has been tested for a protein called HER2 as...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06555471 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been confirmed by laboratory testing to have a specific type of stomach or gastroesophageal junction cancer (where the stomach meets the oesophagus) that is locally advanced, including certain subtypes such as signet ring cell, mucinous, or hepatoid adenocarc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06560528 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to volunteer to take part in the study - People aged 18 to 75 years old (including age 75), of any gender - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed by laboratory testing of ti...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06572319 · Zhejiang Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇨🇳 CN

Who might be able to join this trial: - People who have given written consent to participate in the study - People aged 18 up to (but not including) 75 years old, of any gender - People whose cancer has been confirmed by pathology testing to be adenocarcinoma of the stomach or the junction between the stomach and oesop...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06580574 · Peking University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2029
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older on the day they sign the consent form, of any gender, who are able to understand and voluntarily sign the consent form. - People who have been confirmed through tissue testing to have stomach cancer or colon cancer, with no sign of the cancer spreadin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06597227 · Guihua Wang Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇨🇳 CN

**Note:** The eligibility criteria provided for this trial appear to list the same inclusion criteria twice, with no separate exclusion criteria included in the source document. The information below reflects exactly what was provided. Confirm any exclusion criteria directly with the trial site. --- Who might be able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06597526 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with stomach cancer (gastric adenocarcinoma) confirmed by a tissue sample, and who have not had surgery to remove the primary tumour or any spread of the cancer - People whose stomach cancer has spread to the lining of the abdomen (peritoneal m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06602037 · RenJi Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with pancreatic cancer confirmed by a tissue sample, or imaging scans suggest you may have pancreatic cancer. - You are able and willing to give your signed agreement to take part, including following all the rules and requirements of the study. Who may n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06610799 · Xiangdong Cheng Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2025
🇨🇳 CN

Who might be able to join this trial: - You are between 18 and 75 years old (male or female) - You have advanced or metastatic stomach cancer or cancer at the junction of the stomach and food pipe that has spread and cannot be removed by surgery, and you have not yet received any systemic treatment for it - You have at...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06627634 · Aarhus University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
🇩🇰 DK

Who might be able to join this trial: - People who are older than 18 years of age. - People who have been diagnosed with a specific type of stomach or gastroesophageal junction (the area where the food pipe meets the stomach) cancer called adenocarcinoma, at various stages, with no more than 30% of the liver affected....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06630130 · Jeeyun Lee Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 October 2028
🇰🇷 KR

**Who might be able to join this trial:** - People aged 19 or older - People with a life expectancy of at least 12 weeks - People weighing more than 30 kg (or more than 35 kg for one specific treatment arm) - People who have been diagnosed with a specific type of stomach or stomach-esophagus junction cancer (adenocarc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06632886 · Guo ShiWei Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 October 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing and able to give their agreement to take part and sign a consent form. - People who have already had a CT scan of the abdomen or chest that was done without contrast dye. Who may not be able to join: - People who have been diagnosed with any of the followi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06639490 · Yonsei University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 February 2027
🇰🇷 KR

Who might be able to join this trial: - People who have been diagnosed with stomach cancer and are scheduled to have robot-assisted surgery to remove part or all of the stomach. - Adults aged 20 or older who are able to make their own decisions. - People who are able to have a CT scan done in the specific way required...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06642857 · Xiangdong Cheng Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus (confirmed by biopsy or tissue testing) that has spread or cannot be removed by surgery - People whose cancer has tested negative for a protein called HER2 - People who have not recei...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06645808 · Var2 Pharmaceuticals Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 August 2026
🇳🇱 NL

**Who might be able to join this trial:** - People who are willing to follow all the rules and requirements set out in the study plan - People who are able to give their free and informed agreement to take part, after understanding what the study involves - People who are 18 years of age or older at the time of signin...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06650332 · Zhejiang Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old. - People who have signed an informed consent form agreeing to take part in the trial. - People who have been confirmed by tissue testing to have stomach cancer or cancer at the junction of the stomach and oesophagus that cannot be surgically r...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06653478 · Union Hospital, Tongji Medical College, Huazhong University of Science... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are suspected of having lung cancer or a lung nodule, stomach cancer or a stomach lesion, or colorectal cancer or a colorectal lesion. - People who have signed a consent form agreeing to take part in the trial. - People who have complete and detailed medical record...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06662110 · Shanghai Zhongshan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years, either male or female - People who have recently been diagnosed with a type of stomach cancer called gastric adenocarcinoma, confirmed by a tissue sample (biopsy) - People whose cancer is located in the stomach or where the stomach meets the food pipe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06663319 · Janssen Research & Development, LLC Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 25 February 2028
🇰🇷 KR🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with colorectal cancer (confirmed by a tissue or cell sample) that has spread or cannot be removed by surgery, and it has continued to grow after receiving standard treatments (the exact number of prior treatments required depends on which part of the...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06668454 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 May 2035
🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with a specific type of cancer (adenocarcinoma or squamous cell carcinoma) of the esophagus or the area where the esophagus meets the stomach, confirmed by a tissue biopsy. - Your cancer has spread to a limited number of places in the body — no more t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06669663 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2028
🇬🇧 GB

Who might be able to join this trial: - You are between 18 and 90 years old (male or female) - You have been diagnosed with a type of cancer called adenocarcinoma in your oesophagus (food pipe) or stomach, confirmed by a biopsy, and you are scheduled to have surgery to remove the cancer or a keyhole procedure to check...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06675136 · City of Hope Medical Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 14 January 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have a confirmed diagnosis of stomach (gastric) adenocarcinoma, based on laboratory analysis of a tissue or cell sample - People whose cancer has spread to the lining of the abdomen (peritoneal metastases), visible on a scan or during a keyhole surgical procedure...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06679244 · Huashan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2029
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years old - People whose stomach cancer tumour is located in the upper part of the stomach or at the junction where the oesophagus meets the stomach (a specific type called Siewert II or III), and where surgery is expected to fully remove the tumour - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06685887 · Union Hospital, Tongji Medical College, Huazhong University of Science... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old - You are a man, or a woman who is not pregnant or breastfeeding - You have been diagnosed with stomach cancer confirmed by a medical test (such as a biopsy) - A keyhole (laparoscopic) surgery has confirmed that the cancer has spread to th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06687291 · Karolinska Institutet Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 November 2026
🇸🇪 SE

Who might be able to join this trial: - People who have been diagnosed with cancer of the esophagus (food pipe) or stomach, whether or not they have received chemotherapy or surgery as part of their treatment. - People who are 18 years of age or older at the time of joining the study. - People who are willing to take p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06690112 · Gangnam Severance Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇰🇷 KR

**Who might be able to join this trial:** - You have been diagnosed with stomach (gastric) adenocarcinoma confirmed by a tissue test before surgery. - Your surgeon believes your cancer can be completely removed during surgery. - You have been assessed as fit enough for surgery, with an anesthesia risk score of 3 or bel...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06702683 · Lin Liu Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with stomach cancer (gastric adenocarcinoma) or cancer where the stomach meets the food pipe (gastroesophageal junction adenocarcinoma) - You are planning to receive a medication called Sintilimab as part of your treatment - You are generally able to c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06702891 · Qilu Hospital of Shandong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇳 CN

Who might be able to join this trial: - People who are 18 years of age or older - People who have had an endoscopy and received a confirmed diagnosis of gastric (stomach) cancer — this includes early-stage, advanced-stage, or pre-cancerous changes in the stomach lining - People who have agreed to participate by signing...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06726642 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2029
🇨🇦 CA

**Who might be able to join this trial:** - People who have been confirmed to have one of these inherited cancer risk conditions: Hereditary Breast and Ovarian Cancer (HBOC), Lynch Syndrome, Neurofibromatosis Type 1, Li-Fraumeni Syndrome, PALB2-related cancer risk, or Hereditary Diffuse Gastric Cancer — either through...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06728878 · Jichao Qin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are older than 18 and younger than 85 years of age - People who have been diagnosed with a specific type of stomach cancer called gastric adenocarcinoma, confirmed by a tissue sample taken before surgery - People whose cancer has been assessed before surgery as bei...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06728891 · Jichao Qin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are older than 18 years and younger than 85 years - People who have been diagnosed with a type of stomach cancer called gastric adenocarcinoma, confirmed by a tissue sample taken before surgery - People whose cancer has been assessed before surgery as being at a st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06730373 · Qilu Hospital of Shandong University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years old, of any gender - People who have been confirmed by biopsy or tissue testing to have locally advanced stomach or gastroesophageal junction cancer (where the food pipe meets the stomach) that cannot be surgically removed or has spread to other parts o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06731998 · Allegheny Singer Research Institute (also known as Allegheny Health Ne... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 89 years old - People who are scheduled for a planned (non-emergency) minimally invasive cancer surgery involving the liver, stomach, bile ducts, pancreas, gynecological organs, colon, rectum, or other digestive system organs - People who have given their wr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06732856 · Asan Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇰🇷 KR

**Who might be able to join this trial:** - People who have been newly diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed by a tissue sample, where surgery may be possible - People whose tumour tests positive for a protein called CLDN18.2, based on a specific laboratory te...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06735105 · Yunnan Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with stomach (gastric) cancer confirmed through a tissue sample (biopsy) - People who have not had a biopsy taken within 1 week before the MRI scan, to avoid any bleeding affecting the scan images - People who have no medical reasons preventing them...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06736847 · Jichao Qin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who are older than 18 years and younger than 85 years - People whose pre-surgery tissue testing confirmed a type of stomach cancer called gastric adenocarcinoma - People whose cancer was assessed before surgery as being at a certain stage (not too early and not spread to d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06742411 · West China Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been confirmed (through a tissue or cell sample) to have adenocarcinoma of the stomach or where the stomach meets the food pipe (gastroesophageal junction), including certain subtypes such as signet ring cell, mucinous, or hepatoid adenocarcinoma. - People wh...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06748352 · Shandong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 80 years old. - People who have been confirmed through a tissue test (biopsy) to have either high-grade precancerous changes or a very early-stage cancer limited to the inner lining of the stomach. **Who may not be able to join:** - People whose conditi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06748690 · Peking University People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

Who might be able to join this trial: - People who have a growth located beneath the inner lining of the stomach (called a submucosal tumor) that measures 15mm or larger, as seen during a camera examination of the stomach (endoscopy) Who may not be able to join: - People whose growth does not visibly bulge or protrude...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06755554 · Ukrainian Society of Clinical Oncology Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2026
🇺🇦 UA

**Who might be able to join this trial:** - The cancer has spread to a certain extent within the stomach area, but has not spread to distant parts of the body (confirm with trial site for exact staging details) - You are between 18 and 80 years old - You are male or female - You are generally able to carry out daily ac...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06759064 · Qilu Hospital of Shandong University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with stomach (gastric) adenocarcinoma confirmed by a tissue test (pathology) - People whose fluid build-up in the abdomen (ascites) has been confirmed to contain cancer cells through a fluid sample test - People whose abdominal fluid build-up h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06760858 · Southwest Hospital, China Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have been newly diagnosed with a type of stomach cancer called gastric adenocarcinoma that is HER-2 negative, and you have not had any cancer treatments (such as chemotherapy or radiation) before joining. - You are between 18 and 80 years old and are generally able to ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06766305 · Xiangdong Cheng Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent to take part in the study voluntarily - People whose cancer has been confirmed by a tissue or cell sample (biopsy) as adenocarcinoma (a specific type of cancer) of the stomach or the area where the stomach meets the oesophagus (gastroeso...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06767436 · Yonsei University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 November 2025
🇰🇷 KR

Who might be able to join this trial: - People aged 19 years or older. - People who have been diagnosed with stomach or gastroesophageal cancer (a type called adenocarcinoma) that has spread to other parts of the body, has come back after treatment, or cannot be removed with surgery. - People whose tumor tissue has tes...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06767449 · Yonsei University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇰🇷 KR

**Who might be able to join this trial:** - People who are 19 years of age or older at the time of giving consent. - People who have been diagnosed with a specific type of stomach or stomach-esophagus junction cancer (adenocarcinoma) that has spread, cannot be removed by surgery, or has grown into nearby areas, confir...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06768164 · Assistance Publique - Hôpitaux de Paris Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2031
🇫🇷 FR

Who might be able to join this trial: - You are 18 years old or older, whether male or female - You have been diagnosed with a specific type of stomach cancer (adenocarcinoma of the antrum) that can be treated with surgery aimed at curing the disease by removing part of the stomach - You are registered with the French...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06768463 · University Medical Center Ho Chi Minh City (UMC) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 July 2027
🇻🇳 VN

**Who might be able to join this trial:** - People aged 18 to 75 years old - People who have gastric cancer that has spread to the lining of the abdomen (peritoneum), confirmed by tissue or fluid testing during surgical exploration - People whose cancer spread to the abdominal lining is limited (classified as P1 or P2...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06769425 · Jiangsu Hansoh Pharmaceutical Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 7 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older who have been diagnosed with an advanced solid tumour that has been confirmed by laboratory testing (pathology). - People who have at least one measurable tumour that can be tracked using standard imaging measurements (confirm with trial site). - Peop...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06773312 · Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand the study and are willing to sign a consent form agreeing to take part. - People who are willing and able to follow all study procedures and attend follow-up appointments. - People aged between 18 and 75 years old (inclusive). - People who h...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06774222 · Henan Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who fully understand the study and are willing to sign a consent form agreeing to take part - People aged between 18 and 75 years - People who have been diagnosed through a tissue sample (biopsy) with stomach or gastroesophageal junction cancer that can be surgically r...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06776770 · Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2026
🇨🇳 CN

Who might be able to join this trial: - People who have chosen to take part voluntarily and are willing to sign a consent form. - People aged 18 or older at the time of signing the consent form (any gender). - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus, co...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06778954 · Gangnam Severance Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2025
🇰🇷 KR

**Who might be able to join this trial:** - People who have been confirmed through laboratory testing to have a type of stomach cancer called gastric adenocarcinoma, before having surgery. - People who have had surgery that successfully removed all of the cancer with clear margins (known as a complete or R0 resection)....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06781983 · Innate Pharma Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 April 2028
🇫🇷 FR🇺🇸 US

Who might be able to join this trial: - You have a solid tumor cancer that has been confirmed by lab testing, cannot be removed by surgery, and has spread locally or to other parts of the body, and your tumor is known to produce a protein called Nectin-4. - You have already received treatment for your advanced or sprea...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06782412 · KU Leuven Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇧🇪 BE

**Who might be able to join this trial:** *For the oesophageal or stomach cancer group (OGA):* - People who have given voluntary written consent before any screening takes place (or whose legal representative has done so) - People aged 18 or older - People with a newly confirmed diagnosis of adenocarcinoma of the oeso...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06783569 · JiaRay Group Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2026
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older. - People with a confirmed advanced or spreading solid tumour cancer that has stopped responding to standard treatments, where no standard treatment is available, where standard treatments could not be tolerated, or where the patient has chosen not to rece...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06784752 · Novartis Pharmaceuticals Phase 3 · 12 countries Recruiting
Recruiting Phase 3 Est. completion 8 December 2028
🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇭🇺 HU🇮🇹 IT🇳🇱 NL🇵🇱 PL +4 more

**Who might be able to join this trial:** - People who have been diagnosed within the last 6 months with a type of slow-growing tumour called a gastroenteropancreatic neuroendocrine tumour (GEP-NET) that has spread to other parts of the body or cannot be surgically removed with the aim of a cure, and which has been co...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06784765 · National Research Oncology and Transplantology Center, Kazakhstan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇰🇿 KZ

Who might be able to join this trial: - People who have signed a consent form agreeing to take part in the study - People aged between 18 and 70 years old - People whose general health and ability to carry out daily activities falls within a certain range, known as ECOG performance status 0–2 (confirm with trial site f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06786169 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 September 2026
🇨🇳 CN

Who might be able to join this trial: This trial has three separate groups (cohorts). Each group has different requirements. **Cohort 1 (Surgery followed by chemotherapy)** - People aged 18 to 80 years old who are generally well enough to carry out normal daily activities (ECOG score of 0 or 1) - People diagnosed wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06788548 · Beijing Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2029
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 80 years old (any gender). - Your doctors have assessed that you are well enough for surgery, with good general fitness scores (confirm with trial site if unsure what this means for you). - You have not had any previous stomach or intestinal surgery, c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06791083 · First Affiliated Hospital of Fujian Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have fully understood the study and have chosen to sign a consent form agreeing to take part - People aged 18 to 75 years old (including those aged exactly 18 or 75) - People with a confirmed or potentially surgically removable advanced cancer of the stomach or wh...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06791148 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medic... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent to take part in the study - People aged 18 to 75 years old - People who have been confirmed by tissue testing to have stomach cancer or cancer of the junction between the stomach and food pipe that cannot be surgically removed and has ei...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06791538 · Southwest Hospital, China Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 19 and 74 years old. - A biopsy (tissue sample taken during an internal camera examination) has confirmed you have stomach cancer (a type called adenocarcinoma, which includes several subtypes). - Your stomach cancer has been assessed as locally advanced — mea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06792162 · Peking University Third Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who have been confirmed by tissue testing to have unresectable (cannot be surgically removed) stage III or IV stomach cancer or cancer of the junction between the stomach and oesophagus, where testing shows a specific genetic f...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06792435 · Evopoint Biosciences Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2025
🇨🇳 CN

Who might be able to join this trial: - People who are willing and able to give written consent to participate (or whose legal representative can do so on their behalf). - People aged 18 or older at the time of signing the consent form. - People with a solid tumour that has been confirmed by laboratory testing of tissu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06793917 · Fujian Cancer Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 April 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with advanced, inoperable stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed by tissue testing as a specific type called adenocarcinoma. - People aged between 18 and 70 years old. - People who are relatively well...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06796764 · Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 to 70 years old - People with a Body Mass Index (BMI) of 28 or higher (a measure of body weight relative to height) - People rated as ASA Class I or II — a general health classification meaning either fully healthy or having only mild health conditions (confir...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06798376 · Chinese PLA General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 90 years old who are not bedridden - People who have been confirmed through a biopsy to have stomach cancer or cancer at the junction where the stomach meets the esophagus (a specific type called adenocarcinoma) - People whose cancer was assessed by scan...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06821048 · Weijia Fang, MD Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 or older, of any gender - People who have been diagnosed through tissue testing with an advanced, spreading, or returning cancer — mainly colorectal, esophageal, stomach, pancreatic, lung, or bile duct cancer - People whose cancer has not responded to at least two...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06826079 · Union Hospital, Tongji Medical College, Huazhong University of Science... Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years old (any gender). - People who have given written consent to participate in the trial. - People with laboratory-confirmed, previously untreated HER2-negative stomach cancer or cancer at the junction of the stomach and oesophagus (a specific area wh...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06828588 · Vanderbilt-Ingram Cancer Center Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2027
🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older. - You have cancer that cannot be removed by surgery and has either spread to nearby areas or to other parts of the body, and your doctor has recommended a HER2-targeted treatment as a standard option for your cancer type. - You are either abo...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06830018 · Changchun GeneScience Pharmaceutical Co., Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old. - You are able to carry out basic daily activities, with only mild to moderate limitations in physical activity (confirm with trial site). - Your doctor expects you to live for at least 6 more months. - You have been diagnosed with advance...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06830031 · Shanghai Exuma Biotechnology Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 9 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years (inclusive) - People who are able to understand the study and willing to sign a consent form agreeing to take part - People who are willing to follow the study schedule and requirements throughout the trial - People who have been diagnosed with a s...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06839716 · Gangnam Severance Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇰🇷 KR

Who might be able to join this trial: - People who have been confirmed by laboratory testing to have a type of stomach cancer called gastric adenocarcinoma before surgery - People who have had surgery that completely removed the cancer with no cancer cells left at the edges (a complete removal) - People who have been g...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06841484 · Gangnam Severance Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇰🇷 KR

Who might be able to join this trial: - You have been diagnosed with stomach cancer (specifically a type called gastric adenocarcinoma), confirmed by a tissue test before surgery. - You have had surgery where all of the cancer was completely removed, with no cancer left behind (called an R0 resection). - You have been...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06846346 · UNICANCER Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who have given written consent to take part before any trial procedures begin (if someone is physically unable to sign, a trusted person of their choice may confirm consent in writing on their behalf) - People whose stomach cancer or cancer of the junction between the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06846996 · Daiichi Sankyo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with locally advanced, inoperable, or metastatic stomach cancer or gastroesophageal junction cancer (where the stomach meets the food pipe) confirmed by laboratory testing. - People who are 18 years of age or older at the time of starting the study...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06848400 · Nanfang Hospital, Southern Medical University Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN Hong Kong🇮🇹 IT

Who might be able to join this trial: - People who are 18 years of age or older. - People who are healthy volunteers, OR people experiencing one or more symptoms such as abdominal pain, nausea, vomiting, vomiting blood, black or bloody stools, loss of appetite, bloating, or indigestion, OR people who have previously ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06861244 · University of California, San Francisco Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2030
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a specific type of rare brain tumor called an embryonal tumor with multilayered rosettes (ETMR), confirmed through laboratory testing of tumor tissue. - Sufficient tumor tissue samples must be available (a specific number of tissue slides or a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06869694 · The First Affiliated Hospital of Zhengzhou University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with stomach cancer confirmed by a tissue biopsy. - People who have undergone surgery to remove stomach cancer, including those who had a full removal surgery, or those who had an exploratory or partial surgery where the surgeon found the cancer had...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06873659 · Qurgen Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years old (male or female). - For the early phase of the trial (Phase Ia): People who have been diagnosed with a confirmed solid tumour (any type). For the later phase (Phase Ib): People with either advanced primary liver cancer or advanced primary s...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06881043 · The First Hospital of Jilin University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged over 18 and under 75 years old - People diagnosed with a specific type of stomach cancer called gastric adenocarcinoma (including papillary, tubular, mucinous, signet ring cell, or poorly differentiated types), confirmed by a tissue sample taken during an endosco...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06881511 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with autoimmune gastritis at the Second Affiliated Hospital of Zhejiang University School of Medicine, using the specific diagnostic criteria defined by the trial research team - People whose gastrin levels (a hormone produced in the stomach) are hi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06893133 · Peking University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who have already received pre-surgery treatment (neoadjuvant therapy) followed by surgery that removed all detectable cancer (called R0 resection). - People whose cancer has been confirmed by laboratory testing to be stage II or III stomach cancer or cancer at the junction...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06895447 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 14 November 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years, of any gender. - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and food pipe (called gastroesophageal junction cancer), confirmed by a tissue sample, where the cancer is mainly of a type called adenoca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06896370 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2035
🇨🇳 CN

Who might be able to join this trial: - You are 40 years old or older (any gender can apply) - You are willing and able to give your consent to take part and attend the required check-ups at the start and during follow-up visits Who may not be able to join: - You have previously been diagnosed with stomach cancer or a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06902545 · Astellas Pharma Korea, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2030
🇰🇷 KR

Who might be able to join this trial: - You are currently receiving treatment with VYLOY injection as prescribed and approved in your country. Who may not be able to join: - You have a medical reason that means you should not receive VYLOY injection, based on the official approved guidelines for this medication in you...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06915389 · Qinghai Red Cross Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are 18 years of age or older - People whose overall health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system called ECOG PS 0–2 (confirm with trial site) - People who have been diagnosed wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06921928 · AstraZeneca Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 31 March 2027
🇨🇳 CN🇩🇪 DE🇯🇵 JP🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years old or older at the time of signing the consent form. - You must be generally well enough to carry out light activity and care for yourself, and your condition must not have gotten worse in the 2 weeks before the study begins. - Your doctor believes you...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06925243 · Zuoyi Jiao Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been confirmed by laboratory testing to have a specific type of stomach or gastroesophageal junction cancer (called intestinal type adenocarcinoma) that is HER-2 negative (a specific protein marker test result). - People whose cancer is locally advanced (has...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06926374 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇨🇳 CN

**Who might be able to join this trial:** **General requirements for all procedures:** - People with a body mass index (a measure of body weight relative to height) below 35 - People whose condition is suitable for minimally invasive (keyhole-style) robotic surgery - People who are willing to take part and have signed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06929949 · The First Hospital of Jilin University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 November 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged over 18 and under 75 years old. - People who have had a stomach tissue sample (biopsy) taken by camera examination, with results confirming a specific type of stomach cancer or a pre-cancerous growth called an adenoma. - People diagnosed with early-stage upper st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06937567 · Zhejiang University Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 30 March 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a solid tumor cancer (such as colorectal, stomach, pancreatic, or bile duct cancer, among others), confirmed by a tissue test. - Your cancer has not responded to standard treatments, you were unable to tolerate them, or there are no effective sta...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06940102 · Changchun GeneScience Pharmaceutical Co., Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to sign a written consent form to take part. - People who are 18 years of age or older at the time of joining. - People whose general physical functioning is reasonably well preserved (rated on a standard scale used by doctors to measure how c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06942039 · C17 Council Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 December 2030
🇨🇦 CA

**Who might be able to join this trial:** - A tumor tissue sample must be available for testing. - The patient must be 6 years old or younger at the time their brain or spinal tumor was confirmed by a tissue test (biopsy or surgery). - The patient must have one of the following specific types of brain or spinal tumors...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06943781 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 40 years or older, of any gender - People who have no medical reasons preventing them from having an endoscopy (a procedure where a small camera is used to look inside the digestive tract) and who are able to cooperate with the procedure - People who are able to f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06943807 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 40 years or older, of any gender - People who have no medical reasons preventing them from having an endoscopy (a camera procedure to look inside the digestive tract) and who are able to cooperate during the procedure - People who are able to fully understand and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06945718 · Fujian Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old - People who have been diagnosed with a specific type of stomach cancer called gastric adenocarcinoma (this includes several subtypes such as papillary, tubular, mucinous, signet ring cell, or poorly differentiated), confirmed through...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06947291 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand and voluntarily sign a written consent form - Adults aged 18 years or older - People who have been diagnosed with advanced solid tumour cancers, confirmed through laboratory testing of tissue or cell samples - People whose tumours have been...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06949033 · Zuoyi Jiao Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of stomach or stomach-oesophagus junction cancer (called adenocarcinoma, diffuse or mixed type) that has tested negative for a protein called HER-2. - People whose cancer has not yet been treated and is locally advanced (me...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06961526 · Tanta University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇪🇬 EG

Who might be able to join this trial: - People with confirmed advanced liver cancer (hepatocellular carcinoma), diagnosed through two imaging scans or a liver biopsy, who are eligible for a combination treatment called atezolizumab-bevacizumab. - People whose liver is still functioning reasonably well — specifically, t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06962137 · Universitaire Ziekenhuizen KU Leuven Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2029
🇧🇪 BE

**Who might be able to join this trial:** - You must be at least 18 years old when you sign the consent form - You must be fairly active and able to carry out daily activities with little or no limitation (this is measured by a standard scale called WHO performance status 0–1 — confirm with trial site if unsure) - You...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06962293 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2026
Hong Kong

**Who might be able to join this trial:** - You have a small, surface-level growth (lesion) in your stomach or colon/rectum, and your doctor has planned a procedure called endoscopic submucosal dissection (ESD) — a type of minimally invasive surgery done through a camera tube — to remove it. **Who may not be able to j...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06968221 · Shanghai Cingularbio Co. Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are scheduled to have surgery that involves stapling part of the stomach or joining parts of the bowel together (with or without additional stitching or reinforcement) - You are willing to give your consent to take part and agree to attend follow-up appointments after the...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06984952 · Seoul National University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇰🇷 KR

**Who might be able to join this trial:** - Adults aged 19 years or older who are planning to have a scheduled laparoscopic or robotic surgery to remove part or all of the stomach for stomach cancer - People who are considered to be in generally good to moderate overall health based on a standard medical assessment (ra...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06995898 · National Cancer Institute (NCI) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2029
🇺🇸 US

**Who might be able to join this trial:** - You are between 45 and 75 years old - You agree to give blood samples for possible cancer testing when you join the study and again one year later - You agree to let the study team access relevant information from your medical records - You are able to understand and complete...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06999187 · Dren Bio Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with one of these specific cancer types (confirmed by a laboratory test on tumour tissue): triple-negative breast cancer, HR+/HER2- or HER2+ breast cancer, non-small cell lung cancer, cervical cancer, castration-resistant prostate cancer, pancr...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07001748 · ECOG-ACRIN Cancer Research Group Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 May 2030
🇺🇸 US

**Who might be able to join this trial:** - People who are at least 18 years old. - People whose general physical functioning is rated as good (able to carry out normal daily activities, with at most mild symptoms limiting strenuous activity) — this is measured using a standard medical scale called ECOG, and a score o...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07003334 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing and able to give their voluntary written agreement to participate in the trial - People aged between 18 and 75 years old (inclusive) - People of any sex - People who have been diagnosed with a type of stomach cancer called gastric adenocarcinoma, confirmed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07012447 · yuejun Liu Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - People of any gender are welcome to participate - You must be 14 years old or older - You must have a confirmed diagnosis of one of the following: a specific type of leukemia called ETP-like leukemia, a T-cell leukemia (T-ALL) that also has certain genetic changes linked to a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07018661 · Leiden University Medical Center Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2028
🇳🇱 NL

Who might be able to join this trial: - People who have been confirmed through a stomach camera (gastroscopy) to have a type of stomach cancer called adenocarcinoma, located in the stomach or at the lower junction where the food pipe meets the stomach (a specific subtype called Siewert type III) - People aged 18 years...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07023315 · Akeso Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2029
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and food pipe, confirmed by a laboratory test, where the cancer can be surgically removed and falls within a specific stage range (confirm with trial site for staging details). - Peopl...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07025889 · Ruijin Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to give written consent and to attend the required visits and follow the trial procedures - People who were between 18 and 75 years old at the time of signing the consent form, of any gender - People who have been confirmed by tissue testing to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07026149 · Ruijin Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with stomach or gastroesophageal junction (the area where the food pipe meets the stomach) cancer that has not yet been treated, where the cancer has grown into nearby tissue and spread to lymph nodes but not to other parts of the body - People who...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07026240 · Suzhou Huhu Health & Technology Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 January 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have stomach discomfort and are seeking care at the Gastric Surgery Department at the trial centre - People who have had, or are scheduled to have, a gastroscopy (a camera procedure to look inside the stomach) and/or tissue...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07029269 · Zuoyi Jiao Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2028
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged between 18 and 80 years old - People who have been diagnosed with a type of stomach cancer called gastric adenocarcinoma, confirmed by laboratory testing of tissue - People whose stomach cancer has been assessed as being at a specific stage that has not spread to...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07032961 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to sign a written consent form agreeing to take part - People aged 60 or older who are permanent residents of Guangzhou and have not had a specialist stomach screening in the past three years - People aged 45 or older who have at least one of the follo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07034742 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 January 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a specific type of stomach or gastroesophageal junction (the area where the food pipe meets the stomach) cancer, confirmed by a tissue sample — specifically adenocarcinoma, mucinous adenocarcinoma, or signet ring cell carcinoma. - Your cancer is a...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07035691 · Queen Mary University of London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇬🇧 GB

Who might be able to join this trial: - Adults who have been referred through a fast-track ("2-week wait") or "Straight to Test" referral pathway because lower bowel cancer is suspected. - People aged 18 years or older, of any gender. - People referred through the fast-track pathway who do not have a history of inflamm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07056010 · The First Affiliated Hospital with Nanjing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 November 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years, of any gender. - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus (a specific area called the gastroesophageal junction), confirmed by a tissue sample (biopsy), where the cancer is mainly a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07059299 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2027
🇩🇪 DE

**Who might be able to join this trial:** - People who have signed a written consent form agreeing to take part in the study. - People who are 18 years of age or older at the time they sign the consent form. - People who have been diagnosed through a tissue biopsy with a certain type of stomach, oesophageal, or juncti...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07066657 · ArriVent BioPharma, Inc. Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 May 2029
🇨🇳 CN🇺🇸 US

**Who might be able to join this trial:** - People who are willing to sign a consent form and follow the study requirements - People with a life expectancy of at least 3 months - People who have a tumour tissue sample available for a specific protein test (called CDH17), or who are willing to have a biopsy taken at th...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07067983 · Zhejiang Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are between 18 and 80 years old - People who are already scheduled to have a CT scan of the chest and abdomen area - People who agree to take part willingly and sign a consent form Who may not be able to join: - People who have already been diagnosed with stomach canc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07068607 · Yongquan Shi Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 70 years old (any gender) - You have been confirmed to have a *Helicobacter pylori* (H. pylori) stomach infection through a breath test, a rapid test, or a stool test - You have never received any treatment to get rid of an H. pylori infection before -...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07069712 · AstraZeneca Phase 2 · 11 countries Recruiting
Recruiting Phase 2 Est. completion 28 January 2027
🇨🇦 CA🇨🇳 CN🇬🇪 GE🇮🇹 IT🇯🇵 JP🇵🇱 PL🇪🇸 ES🇹🇼 TW +3 more

**Who might be able to join this trial:** - People who have been diagnosed with stomach cancer, cancer at the junction of the stomach and food pipe (GEJ), or cancer of the food pipe (esophageal adenocarcinoma), where the cancer can be surgically removed - People whose cancer tests positive for a protein called CLDN18.2...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07069842 · Changzhi People's Hospital Affiliated to Changzhi Medical College Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 who have been diagnosed with advanced stomach cancer or cancer at the junction of the stomach and oesophagus that cannot be surgically removed, or that has spread to other parts of the body, confirmed by laboratory tissue testing. - People who are planned...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07070466 · Massachusetts General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of cancer (adenocarcinoma) of the esophagus, the junction between the esophagus and stomach, or the stomach — but not squamous cell tumors, and not tumors that test positive for a protein called HER2. - People whose cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07076979 · Shanghai Minimally Invasive Surgery Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇨🇳 CN

**Who might be able to join this trial:** *As a Healthy Volunteer:* - You are over 18 years old - You are willing to participate and able to sign a consent form *As a Gastric Cancer Patient:* - You are 18 years old or older - You are generally well enough to carry out daily activities with little or no limitation (co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07078136 · Huazhong University of Science and Technology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 years or older - People who have been found to have a growth beneath the lining of the upper digestive tract (such as the stomach or esophagus), detected by a standard camera examination of the digestive tract (endoscopy), and who have also had a specialised u...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07091617 · Alliance for Clinical Trials in Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 April 2028
🇺🇸 US

**Who might be able to join this trial:** **For patients:** - People who are between 18 and 39 years old at the time of joining the trial - People who have had a cancer diagnosis at any age up to 39, including those who were recently diagnosed, are currently in treatment, or have finished treatment — people with cance...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07098026 · Hunan Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of stomach or stomach-oesophagus junction cancer (called adenocarcinoma), confirmed by tissue or cell testing - People whose cancer is removable by surgery, or potentially removable, and has reached a certain stage of sprea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07103668 · Suzhou Immunofoco Biotechnology Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 May 2027
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older, of any gender - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus that cannot be surgically removed, has spread, and has not responded to at least two prior treatment regimens (or one prior regimen...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07108855 · University Medical Center Groningen Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇳🇱 NL

Who might be able to join this trial: - People who have been diagnosed with an early-stage (surface-level) cancer of the oesophagus and/or stomach, specifically a type called adenocarcinoma at stage T1, and who are scheduled for a procedure called ESD (a type of endoscopic surgery to remove the affected tissue) at the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07110571 · Suzhou Suncadia Biopharmaceuticals Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus (confirmed by a tissue test), and who have not yet received any cancer treatment for this condition. - People aged 18 to 70 years old, of any gender. - People who are able t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07114601 · Eli Lilly and Company Phase 1 · 7 countries Recruiting
Recruiting Phase 1 Est. completion 1 April 2030
🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇯🇵 JP🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People who have been confirmed through a tissue or cell sample to have locally advanced, inoperable, or cancer that has spread to other parts of the body. - People whose scans (CT or MRI) show at least one measurable tumour, or — if only bone involvement is present — at leas...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07114627 · Erasmus Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇳🇱 NL

Who might be able to join this trial: - People who are 18 years of age or older - People who are planned to start a combination treatment using two chemotherapy medicines called capecitabine and oxaliplatin as part of their standard care (any dose) - People whose treating doctor has assessed them as suitable to receive...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07119463 · The First Hospital of Jilin University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People between 18 and 80 years old who are scheduled to have surgery for stomach cancer - People whose stomach cancer has been confirmed by a laboratory tissue test (pathology), regardless of the specific type of stomach cancer - People whose cancer has been assessed by a CT...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07124351 · Cedars-Sinai Medical Center Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older, of any sex - People who have been diagnosed with, or are strongly suspected of having, cancer of the stomach or oesophagus (gastroesophageal adenocarcinoma), based on CT, PET, or other scans (Cohort 1) — or people diagnosed with appendix cancer (appe...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07124754 · Qun Zhao Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
🇨🇳 CN

Who might be able to join this trial: - You must be 18 years old or older - You have been diagnosed with stomach cancer (specifically a type called gastric adenocarcinoma), confirmed through a laboratory test of tissue samples - Your cancer is at an early stage (T1, either T1a or T1b), confirmed by a camera examination...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07133490 · Erasmus Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇳🇱 NL

**Who might be able to join this trial:** - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and food pipe, confirmed by a tissue sample - People whose cancer has spread to the lining of the abdomen (the peritoneum), confirmed by both lab results and clinical assessment, with...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07139366 · Yongquan Shi Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years, of any gender - People whose previous attempts to clear an H. pylori infection with treatment have not worked - Women of childbearing age may be eligible if they are not pregnant or breastfeeding, and are willing to use an accepted form of...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07139418 · Jichao Qin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are older than 18 years and younger than 85 years - People who have been diagnosed with a specific type of stomach cancer called gastric adenocarcinoma, confirmed by a tissue sample taken before surgery - People whose cancer is at a certain stage before surgery — n...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07149090 · Asan Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 July 2027
🇰🇷 KR

**Who might be able to join this trial:** - People who have been newly diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus that has spread to other parts of the body, cannot be surgically removed, or has come back - People whose cancer has spread to the lining of the abdomen and who h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07150546 · Emory University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 September 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who are able to give written consent to take part in the study - People who have a neuroendocrine tumour that has been confirmed by a pathology test, is well-differentiated and classified as grade 1 or 2, and cannot be surgical...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07151040 · One-carbon Therapeutics AB Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇫🇷 FR🇪🇸 ES🇬🇧 GB

Who might be able to join this trial: - People who have given written consent to participate in the study - People who have been diagnosed with advanced cancer confirmed by laboratory tissue testing — specifically colorectal cancer, head and neck squamous cell cancer, non-small cell lung cancer, or gastric cancer (incl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07158164 · Rutgers, The State University of New Jersey Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 7 July 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with cancer (either early-stage requiring additional treatment after surgery, or cancer that has spread) and your doctor plans to start you on a chemotherapy drug called 5-FU or Capecitabine. - You have already had a specific genetic test (called a DPY...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07161479 · Samsung Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇰🇷 KR

**Who might be able to join this trial:** - Adults aged 20 years or older - People who have been diagnosed with a type of non-cancerous stomach growth called a gastric adenoma with low-grade changes (meaning the cells look mildly abnormal but not cancerous), and where the growth measures 1 cm or smaller on camera exami...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07165132 · RayzeBio, Inc. Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 February 2027
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People who are at least 18 years old at the time of signing the study consent form - People who have a tissue-confirmed diagnosis of a well-differentiated (slow-growing) neuroendocrine tumour (NET) that has spread or cannot be surgically removed — this applies across various...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07165847 · Daping Hospital and the Research Institute of Surgery of the Third Mil... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 23 September 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand and voluntarily sign a written consent form before any study procedures begin. - People who are 18 years of age or older at the time of signing the consent form, of any gender. - People who have been confirmed by tissue testing to have a typ...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07176312 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2029
🇩🇪 DE

**Who might be able to join this trial:** - People who have signed and dated an informed consent form before any trial-related procedures begin, in line with the required guidelines. - People who, in the trial doctor's judgement, are willing and able to attend scheduled visits, follow the treatment plan, and complete...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07176624 · The First Hospital of Jilin University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 August 2027
🇨🇳 CN

Who might be able to join this trial: - People who are 18 years of age or older - People who have had at least one organ system begin to fail within the first 24 hours of being admitted to an intensive care unit (ICU), as measured by a standard medical scoring tool (confirm with trial site) - People diagnosed with mode...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07178808 · Banner Health Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 22 February 2031
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older (there is no maximum age limit) - You are able to carry out basic daily activities and are not fully disabled (your doctor will assess this using a standard scale — confirm with trial site) - You have been confirmed by a lab test (from a tissu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07179692 · Chongqing Precision Biotech Co., Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 March 2028
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older, of any gender - People who have been confirmed by tissue testing to have an advanced, spreading, or returning cancer — mainly colorectal, esophageal, stomach, pancreatic, lung, or bile duct cancer - People whose cancer has not responded to at least two pr...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07183150 · Tianjin Medical University Cancer Institute and Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old - People who have been diagnosed with stomach cancer confirmed by a laboratory tissue test - People who have had a specific type of stomach cancer surgery that removes the cancer completely, including at least 16 lymph nodes (called D2, R0 radi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07192432 · Vironexis Biotherapeutics Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2033
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have a HER-2 positive solid tumour that has been confirmed through laboratory testing of tissue or cell samples - For Part 1 of the trial: people whose advanced or metastatic cancer (cancer that has spread) has continued t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07194005 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2028
🇨🇳 CN

Who might be able to join this trial: - People who have voluntarily agreed to take part and have signed a consent form - People aged 18 to 70 years (inclusive), of any gender - People who have been confirmed by tissue or cell testing to have stomach cancer or cancer at the junction of the stomach and oesophagus that ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07212933 · Chinese PLA General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and are happy to sign a consent form agreeing to join the study - You are aged 18 to 70 years old - You have been diagnosed with Stage IV (advanced/spread) stomach cancer or cancer at the junction of the stomach and food pipe, confirmed by a came...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07213791 · Eli Lilly and Company Phase 1 · 5 countries Recruiting
Recruiting Phase 1 Est. completion 1 July 2028
🇨🇳 CN🇩🇪 DE🇯🇵 JP🇳🇱 NL🇺🇸 US

**Who might be able to join this trial:** - Your cancer must show signs of a specific protein called FAP (fibroblast activation protein), confirmed through a scan or clinical assessment. - You must have a confirmed diagnosis of one of these cancer types: pancreatic cancer (adenocarcinoma), hormone receptor-positive/HE...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07223424 · Diwakar Davar Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2030
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to read, understand, and sign a written consent form in English. - You are able to read and write in English. - Your doctor has determined that you are medically suitable to receive either nivolumab or pembrolizumab, either on its own or combined wit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07224750 · City of Hope Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 June 2028
🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older at the time your blood sample is collected. - You have been officially diagnosed with one of the following cancers: liver cancer (HCC), bile duct cancer (CCA), pancreatic cancer (PDAC), esophageal cancer (ESCC), stomach cancer (GC), or bowel/c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07227168 · Sutro Biopharma, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with certain advanced or spreading solid tumour cancers, confirmed by laboratory testing of tissue or cells. The specific cancer types included are: head and neck squamous cell carcinoma, non-small cell lung cancer, esophageal or gastric (stomac...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07233447 · Centre Hospitalier Universitaire de la Guadeloupe Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 February 2027
Guadeloupe

Who might be able to join this trial: - People who are over 18 years old, have been living in Guadeloupe for more than 6 months, and have a primary diagnosis of stomach cancer - People who have read the information sheet about the study and have signed a consent form agreeing to take part - People who are covered by so...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07243015 · City of Hope Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 June 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with stomach cancer (specifically a type called gastric adenocarcinoma), confirmed through laboratory testing of tissue samples - People who have had surgery with the goal of fully removing the cancer (meaning no cancer was left behind at the edges...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07245095 · Hospital General de Mexicali Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2026
🇲🇽 MX

Who might be able to join this trial: - You are between 18 and 70 years old (male or female) - You are willing to take part in the clinical trial - You do not currently have active bleeding in your stomach or intestines - You are willing to sign a consent form agreeing to participate Who may not be able to join: - You...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07250347 · The First Affiliated Hospital with Nanjing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2028
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with stomach (gastric) cancer confirmed by a tissue sample analysis - People who had a CT scan with contrast dye done before their surgery - People who showed no signs of cancer having spread to other parts of the body at the time of initial staging...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07259226 · UNICANCER Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2030
🇫🇷 FR

**Who might be able to join this trial:** - People who have signed a written consent form before any trial-related procedures take place. - People aged 18 or older. - People with a confirmed diagnosis of unresectable locally advanced or metastatic cancer — specifically breast, bladder (urothelial), non-small cell lung...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07263386 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to sign a written consent form before any study-related procedures begin. - People aged between 18 and 75 years. - People who have had surgery to remove their stomach cancer, including removal of nearby lymph nodes (D2 or more extensive dissec...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07270991 · Federation Francophone de Cancerologie Digestive Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 30 November 2030
🇫🇷 FR🇩🇪 DE

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender. - People who have been confirmed by tissue testing to have a type of cancer called adenocarcinoma that has spread (metastatic), originating from the stomach, the junction between the oesophagus and stomach, or the oesophagus. - People...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07282912 · Yale University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with Stage IV cancer of the esophagus, stomach, pancreas, bile ducts (inside or outside the liver), gallbladder, small intestine (duodenum), or the area where the bile duct meets the small intestine (ampulla), confirmed by a tissue sample. - People...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07283939 · Alliance for Clinical Trials in Oncology Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 May 2030
Guam Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with invasive cancer that has been confirmed or is suspected to have started in the gastrointestinal (digestive) tract — this includes cancers of the esophagus, stomach junction, stomach, small intestine, a part of the digestive system called t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07284186 · Plexium, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2029
🇺🇸 US

Who might be able to join this trial: - People who have a solid tumour (cancer) that has spread to nearby tissue or to other parts of the body, has come back after treatment, or has not responded to treatment, and whose tumour has a specific genetic change called a SMARCA4 loss-of-function mutation - People whose cance...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07289997 · Hebei Medical University Fourth Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part voluntarily and sign a consent form - You are 18 years old or older (any gender) - You have been diagnosed (through a tissue or cell sample) with a type of stomach or gastroesophageal junction cancer called adenocarcinoma that cannot be surgicall...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07294638 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with early-stage stomach cancer (specifically a type called adenocarcinoma) that has been confirmed through laboratory testing of tissue or cell samples - People whose cancer is at an early enough stage (classified as cT1 or cT2) and whose tumor mea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07294664 · The First Affiliated Hospital of Zhengzhou University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have agreed to take part voluntarily and have signed a consent form - People aged 18 or older - People whose general physical functioning is reasonably well-preserved (rated 0–2 on a standard medical scale, meaning they are able to carry out at least some daily ac...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07295236 · Ukrainian Society of Clinical Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇺🇦 UA

Who might be able to join this trial: - People who developed a leak at the surgical connection between the food pipe (esophagus) and the small intestine (jejunum), where the leak affects less than half of the connection's opening - People who developed this type of surgical leak but are otherwise stable and do not need...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07298200 · Jia Wei Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are willing and able to sign and date a consent form agreeing to take part. - You are between 18 and 70 years old (male or female). - You have been diagnosed with advanced stomach cancer confirmed by a lab test (biopsy or cell sample), and your cancer has not responded t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07302100 · University Hospital, Strasbourg, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇫🇷 FR

Who might be able to join this trial: - Adults between 18 and 70 years of age - People who have been diagnosed with a neuroendocrine tumor of the digestive system (specifically in the stomach, pancreas, or intestine) between January 1, 2000, and November 30, 2024, and are currently being monitored for it Who may not b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07304271 · Magnus Nilsson Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 31 January 2031
🇮🇹 IT🇳🇱 NL🇸🇪 SE

**Who might be able to join this trial:** - People diagnosed with a specific type of stomach or stomach-oesophagus junction cancer (called adenocarcinoma, in specific locations known as Siewert type II or III), confirmed by a tissue or fluid sample from the tumour - People whose cancer has spread to the lining of the...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07307560 · Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older - People who score 5 or higher on the STOP-Bang questionnaire, which is a screening tool used to assess the likelihood of sleep apnea - People who are already scheduled to have a sedated gastrointestinal endoscopy procedure (such as a gastroscopy, col...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07309185 · Shandong Tumor Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with advanced stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed by a tissue or cell sample. - People whose cancer has stopped responding to a first round of treatment that included both chemotherapy and immune-based t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07310888 · Chinese University of Hong Kong Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 30 December 2027
Hong Kong🇯🇵 JP

Who might be able to join this trial: - Adults between 18 and 75 years of age - People with a body mass index (a measure of body weight relative to height) below 35 - People who have been recently diagnosed with a tumor of the stomach or the area where the stomach meets the esophagus, and who are planned to have a sche...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07311408 · Jingdong Zhang Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, of any sex - People who have been formally diagnosed (through tissue testing) with stomach cancer or cancer at the junction where the oesophagus meets the stomach (gastroesophageal junction adenocarcinoma) - People whose cancer has gotten worse durin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07312760 · Universitätsklinikum Hamburg-Eppendorf Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with a solid tumour (stage III or IV) or an advanced blood cancer - You are well enough at the start of treatment to attend appointments as an outpatient (without being admitted to hospital) - You are experiencing significant emotional distress related...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07315750 · RemeGen Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2029
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily and sign a consent form - People with a life expectancy of more than 12 weeks - People who are fully active or have only minor restrictions in daily physical activity (as measured by a standard medical scoring system called ECOG...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07315854 · Beijing Friendship Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily, have been fully informed about the study, and are willing and able to follow all trial procedures. - People aged 18 to 80 years old (any gender). - People who have been confirmed by imaging and tissue testing to have stomach c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07317505 · Conjupro Biotherapeutics, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2029
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with a solid tumor (confirmed by laboratory testing of tissue or cells) that has spread locally or to other parts of the body, and standard treatments have not worked, you cannot tolerate them, or no standard treatmen...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07320586 · Shandong Tumor Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old, of any gender - People diagnosed with stomach cancer (gastric adenocarcinoma) or cancer where the stomach meets the oesophagus (gastroesophageal junction adenocarcinoma), confirmed by a tissue or cell test - People whose cancer has progressed...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07325630 · Zhejiang Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and have signed a consent form agreeing to join the study - You are between 18 and 75 years old - You have been diagnosed with stomach cancer or cancer at the junction of the stomach and food pipe, confirmed by a tissue test - Your cancer cells h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07334431 · Henan Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have read and fully understood the study information and have freely agreed to take part by signing a consent form - You are between 18 and 75 years old (inclusive) - You have been diagnosed through a biopsy or tissue test with advanced stomach cancer or cancer at the ju...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07353684 · Beijing Friendship Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old at the time of joining, with a life expectancy of at least 3 months. - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed by laboratory testing of tissue or cell samples, and ma...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07354711 · 3H Pharmaceuticals Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to sign the consent form and follow the study schedule and requirements. - People aged 18 or older at the time of signing the consent form. - People who have at least one tumour or lesion that can be measured on a scan, according to standard me...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07358806 · Oscotec Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇰🇷 KR

**Who might be able to join this trial:** - You are 18 years of age or older (or 19 or older, depending on local rules) at the time of screening - You are willing and able to sign a consent form before any study-related procedures begin - Your doctor believes you are likely to live for more than 12 weeks - Your blood...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07360314 · EMD Serono Research & Development Institute, Inc. Phase 1 · 4 countries Recruiting
Recruiting Phase 1 Est. completion 20 September 2028
🇨🇦 CA🇯🇵 JP🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with an advanced solid tumour (confirmed by laboratory testing of tumour tissue) that has a high level of a protein called Ly6E. - People whose tumour cannot be surgically removed and has either spread to other parts of the body or is locally a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07362186 · LaNova Medicines Limited Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 17 August 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part and agree to sign a consent form before any study procedures begin - People aged 18 or older, of any sex - People who weigh at least 40 kg or have a body mass index (BMI) of 18.5 or above - People whose general health and ability to carry...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07366528 · Ruijin Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 October 2028
🇨🇳 CN

**Who might be able to join this trial:** - People between 18 and 80 years old, of any gender - People who have been confirmed through laboratory testing to have a specific type of stomach or gastroesophageal junction cancer called adenocarcinoma - People who have already had a standard type of stomach surgery (called...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07371663 · Beijing Tide Pharmaceutical Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily and sign a consent form - People who are 18 years of age or older at the time of signing the consent form - People who have been confirmed by tissue or cell testing to have advanced or metastatic solid tumours, and whose cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07374731 · Centro di Riferimento Oncologico - Aviano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇮🇹 IT

**Who might be able to join this trial:** - You are 18 years of age or older - You are able to understand, agree to, and sign the main consent form for the study - You are able to understand, agree to, and sign a consent form allowing your data to be used - You are able to understand, agree to, and sign a consent form...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07385703 · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co.,... Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older who are willing and able to follow the study schedule, including visits, treatments, and tests. - People who have been diagnosed with a specific type of stomach or gastroesophageal junction cancer (adenocarcinoma) confirmed by laboratory testing of ti...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07389876 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 80 years old (inclusive), of any gender - People with stomach cancer or cancer of the gastroesophageal junction (where the stomach meets the food pipe) that has been confirmed by a tissue or cell sample, and cannot be removed by surgery or has spre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07390838 · Nanjing Sanhome Pharmaceutical, Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 December 2026
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older, of any gender, who give their informed consent to participate. - People with a confirmed diagnosis (through tissue testing) of a locally advanced, returning, or spread solid tumour — such as colorectal, stomach, liver, head and neck, breast, lung, oesopha...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07392346 · Dai, Guanghai Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older - People who have been confirmed by laboratory testing (from tissue or cell samples) to have stomach cancer or cancer where the stomach meets the oesophagus - People whose cancer stopped responding to a first round of treatment that included a type of...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07392892 · Pfizer Phase 3 · 6 countries Recruiting
Recruiting Phase 3 Est. completion 22 July 2031
🇨🇳 CN🇮🇱 IL🇯🇵 JP Puerto Rico🇹🇼 TW🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with stomach cancer, cancer of the gastroesophageal junction (where the stomach meets the oesophagus), or oesophageal adenocarcinoma, confirmed by a tissue or cell sample. - People whose cancer has spread to nearby areas or to other parts of the...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07400354 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 14 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, any gender - People whose general health and ability to carry out daily activities falls within an acceptable range (scored 0–2 on a standard oncology scale), with a life expectancy of more than 3 months - People who have been diagnosed with stomach...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07401173 · Qun Zhao Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older - People who have been diagnosed with a specific type of stomach cancer (gastric adenocarcinoma) confirmed through a tissue test - People who are scheduled for planned stomach cancer removal surgery intended to fully remove the cancer (open, keyhole, o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07406633 · Kumquat Biosciences Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with a type of tumour called GIST (gastrointestinal stromal tumour) that cannot be surgically removed or has spread to other parts of the body - People whose GIST diagnosis has been confirmed through tissue testing - People whose blood or tumour tissue test r...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07411118 · Chinese University of Hong Kong Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2032
🇨🇳 CN Hong Kong🇮🇳 IN🇯🇵 JP

**Who might be able to join this trial:** - Adults aged 18 to 75 years who have been diagnosed with a gastric GIST (a type of stomach tumour) and have chosen to have it removed using an endoscopic procedure (a procedure done through the mouth using a flexible camera) - People who have a growth found beneath the inner...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07432295 · I-Mab Biopharma US Limited Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 March 2030
🇨🇳 CN🇯🇵 JP🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with stomach cancer, cancer of the gastroesophageal junction (where the stomach meets the esophagus), or esophageal adenocarcinoma that cannot be removed by surgery or has spread to other parts of the body, confirmed by a tissue biopsy. - You have not...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07432633 · Blue Earth Diagnostics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 79 years old who are able to give their consent to take part and are willing to follow all study requirements. - People who are well enough to carry out basic daily activities, with a general health score within an acceptable range as assessed by a doctor (...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07441785 · P. Herzen Moscow Oncology Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇷🇺 RU

Who might be able to join this trial: - People who have been diagnosed with a cancer of the stomach or the junction between the oesophagus (food pipe) and stomach (including certain types called Siewert I and II), where the cancer has not spread to distant parts of the body - People whose planned surgery involves remov...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07441850 · Beijing Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 70 years old - You have been diagnosed with a specific type of stomach or food pipe (oesophago-gastric junction) cancer, confirmed by a tissue sample, that can be removed with surgery - A team of specialist doctors (a multidisciplinary team) has recomme...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07454642 · Avacta Life Sciences Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been fully informed about the study and are willing and able to sign a consent form - Adults aged 18 or older - People who have one of the following cancer types that has been confirmed by lab testing, is locally advanced (cannot be surgically removed) and/or...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07464756 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 May 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have chosen to take part voluntarily and have signed a consent form - People aged 18 years or older - People who have been confirmed by laboratory testing to have stomach cancer (gastric adenocarcinoma) or cancer at the junction where the stomach meets the oesopha...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07474324 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years - People who have had surgery to fully remove their stomach cancer, including removal of surrounding lymph nodes (called D2 or wider dissection), with no cancer left behind after surgery - People who did not receive any cancer treatment (s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07481110 · Société Algérienne de Formation et Recherche en Oncologie Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 August 2026
Algeria

Who might be able to join this trial: - People aged 19 years or older - People who have been diagnosed with stomach (gastric) cancer confirmed through a tissue sample test (biopsy) - People who are being treated or monitored at one of the oncology departments taking part in this trial - People who have given their info...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07481357 · Dong-A ST Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 February 2028
🇰🇷 KR

Who might be able to join this trial: - You must be 19 years of age or older - You must have been diagnosed with a specific type of advanced stomach cancer or cancer at the junction of the stomach and food pipe, or advanced pancreatic cancer, that has tested positive for a protein called CLDN18.2 (confirmed through a t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07483554 · Innovent Biologics (Suzhou) Co. Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to sign a consent form and are able to attend the required visits and follow the study procedures - People who have at least one tumour that can be measured using standard imaging criteria (called RECIST v1.1) - People aged 18 or older (any gender) - P...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07488611 · Soonchunhyang University Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2027
🇰🇷 KR

**Who might be able to join this trial:** - Adults aged 19 years or older who are scheduled to have surgery for gastric (stomach) cancer. - People who have given their written agreement to take part in this study. **Who may not be able to join:** - People who have a serious uncontrolled illness, such as poorly managed...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07488676 · Astellas Pharma Global Development, Inc. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 31 July 2029
🇯🇵 JP🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with one of the following cancer types, confirmed by laboratory tissue analysis: stomach, gastroesophageal junction (GEJ), or esophageal adenocarcinoma; pancreatic adenocarcinoma; or one of several other cancer types including bile duct cancer,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07492615 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 20 February 2029
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with stomach cancer or cancer at the junction of the stomach and esophagus, confirmed by a tissue sample (biopsy) - Your cancer has been classified as a specific stage (stage IIIA, IIIB, or IIIC) based on pathology resu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07504367 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are junior doctors holding a valid practicing physician qualification certificate. - People who are oncologists, surgeons, radiation oncologists, radiologists, or pathologists with between 3 and 5 years of clinical experience. - People who are between 25 and 33 years o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07504913 · Parc de Salut Mar Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇪🇸 ES

**Who might be able to join this trial:** - You have had surgery to treat stomach (gastric) cancer with the goal of removing the cancer completely, and it took place between 1 month ago and up to 5 years ago - You are 18 years of age or older - Your stomach cancer has not come back after surgery - You have agreed to ta...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07517107 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed by a tissue or cell sample - People with a general health and activity level rated as reasonably functional (a score of 0–2 on a st...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07517198 · Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuti... Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 March 2029
🇺🇸 US

Who might be able to join this trial: - You are generally able to carry out daily activities and care for yourself with little or no limitation (doctors use a scale called ECOG to measure this, and a score of 0 or 1 is needed). - You have been diagnosed with one of the following cancers, confirmed by a tissue or biopsy...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07517432 · Chinese University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2031
Hong Kong

Who might be able to join this trial: - You have been diagnosed with stomach (gastric) cancer and are having a specific type of robot-assisted minimally invasive stomach surgery at a participating centre Who may not be able to join: - There are no specific exclusion criteria listed for this trial (confirm with trial s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07518147 · Sichuan Baili Pharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2029
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to sign a consent form and agree to follow the study rules - You are between 18 and 75 years old - Your doctors expect you to live for at least 3 months - You have been diagnosed with stomach cancer or cancer at the junction of the stomach and food pipe that...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07522151 · Shanghai Shengdi Pharmaceutical Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2029
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed by laboratory testing of tissue samples. - People aged 18 or older but under 75 years old — both men and women are eligible. - People whose doctor has assess...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07525765 · First Affiliated Hospital of Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with stomach (gastric) cancer, confirmed through laboratory testing of tissue samples - People who have had surgery to remove part or all of the stomach as a cancer treatment - People who are willing and abl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07529808 · BigHat Biosciences, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older (or meet the legal age of consent where the trial is taking place) - You have been diagnosed with advanced stomach cancer or cancer where the stomach meets the esophagus (gastroesophageal junction), confirmed by a lab test, and your cancer has g...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07537348 · Qilu Hospital of Shandong University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with advanced stomach cancer that has spread to other parts of the body, confirmed by scans (such as CT or PET-CT), and your doctors have recommended a treatment plan that combines chemotherapy and immunotherapy. - You are between 18 and 70 years old (...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07537361 · Qilu Hospital of Shandong University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - Your stomach cancer has been confirmed by a tissue biopsy showing it is locally advanced. - You are between 18 and 70 years old (any gender). - You are able to eat by mouth or receive liquid nutrition through a tube placed through your nose into your stomach. - You are willin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07540026 · National Cheng-Kung University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇹🇼 TW

Who might be able to join this trial: - Adults aged 18 or older who are scheduled to have an endoscopy procedure to treat bleeding from an upper digestive tract tumour Who may not be able to join: - People who do not need an endoscopic procedure to stop their bleeding - People who have a known allergy to sucralfate (a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07542652 · Yongquan Shi Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 75 years old, of any gender - People who have received a first-time diagnosis in the last three months of either chronic non-atrophic gastritis (a type of stomach inflammation), precancerous changes in the stomach lining, or stomach cancer - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07544589 · Dispatch Biotherapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 April 2046
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with advanced or spreading cancer of the esophagus, the junction between the esophagus and stomach, the stomach, or the colon/rectum — confirmed by a tissue sample (biopsy) - People whose cancer can be measured on scans (according to a standard...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07547787 · Akeso Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2030
🇨🇳 CN

Who might be able to join this trial: - People who are able to understand and are willing to sign a written consent form before any study procedures begin. - People who previously took part in a sponsor-run clinical trial that involved a treatment called cadonilimab (also known as AK104), and where that original trial...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07551466 · The First Affiliated Hospital of Soochow University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - You are 18 years of age or older - A suspicious area in your stomach was spotted during a standard camera examination (called white-light imaging) - A tissue sample (biopsy) taken before any procedure showed either pre-cancerous changes or early stomach cancer, and you also had a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07552402 · Harbin Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years old, of any sex - People who have been diagnosed with advanced stomach cancer or cancer at the junction of the stomach and food pipe (confirmed by laboratory testing of tissue or cells), where the cancer stopped responding to — or caused unacce...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07556640 · Ruijin Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with stomach cancer or cancer at the junction of the stomach and food pipe, confirmed by a tissue sample (biopsy), that is HER2-negative (a specific cancer type), and you have not had surgery to remove the cancer - You are 18 years of age or older - Yo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07561073 · Guangxi Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇨🇳 CN

**Who might be able to join this trial:** - Patients and their families have been fully informed about the study and have voluntarily agreed to take part by signing a consent form. - People aged between 18 and 75 years old (including those who are exactly 18 or 75). - People who have been diagnosed through tissue test...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07584577 · University Hospital, Bordeaux Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇫🇷 FR

Who might be able to join this trial: - People who are having surgery for esophageal cancer - People who are malnourished at the time of their treatment - People who are receiving neoadjuvant treatment (treatment given before the main surgery, such as chemotherapy or radiation) (confirm with trial site) Who may not be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07586384 · First Affiliated Hospital of Wenzhou Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (inclusive). - You are generally able to carry out some daily activities and care for yourself (your doctor will assess your overall physical functioning level). - You have been diagnosed with a specific type of stomach cancer near the uppe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07587229 · City of Hope Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with stage II or III stomach cancer, confirmed by laboratory testing of tissue - People who have had surgery aimed at fully removing the cancer - People who have received a type of chemotherapy called 5-FU (fluorouracil) after their surgery to help...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07593820 · Vall d'Hebron Institute of Oncology Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2030
🇪🇸 ES

**Who might be able to join this trial:** - People aged 18 or older who are willing and able to give written consent before any study procedures begin. - People who are able and willing to attend all required study visits and follow the study requirements. - People whose cancer-related physical condition is rated as f...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07595237 · SmartNuclide Biopharma Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 24 November 2025
🇨🇳 CN

Who might be able to join this trial: - You are between 18 and 75 years old (inclusive) - You are able to make your own decisions and are willing to sign a consent form to take part voluntarily - You are generally able to carry out light activity and care for yourself (a standard fitness scale called ECOG rates you as...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07607119 · Samsung Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2028
🇰🇷 KR

Who might be able to join this trial: - People aged 19 years or older - People with a general health and activity level rated as 0, 1, or 2 on a standard oncology scale (called ECOG Performance Status), meaning they are able to carry out at least some daily activities - People who have been confirmed through laboratory...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07631000 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 27 May 2029
🇺🇸 US

Who might be able to join this trial: - People who are able to give signed consent to participate. - People who are 18 years of age or older at the time of giving consent. - People who are generally well enough to carry out daily activities with little or no limitation (measured by a standard health scale called ECOG,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07635316 · Novartis Pharmaceuticals Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 February 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a type of cancer called a gastroenteropancreatic neuroendocrine tumour (GEP-NET), recorded in medical records at some point between 1 January 2018 and 31 December 2025. - People who started a first course of treatment for GEP-NET — such as cert...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07646106 · Thena Biotech S.r.l. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2027
🇮🇹 IT

**Who might be able to join this trial:** - People who have given written consent to participate - Adults aged 18 or older, of any gender - People who have been diagnosed with a solid tumour — the trial is particularly interested in small cell lung cancer, colorectal cancer, pancreatic adenocarcinoma, gastric (stomach...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07651644 · Liaoning Cancer Hospital & Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 July 2026
🇨🇳 CN

Who might be able to join this trial: **For patient imaging data to be included:** - CT scan images (with contrast dye) must come from gastric cancer patients treated at Liaoning Cancer Hospital - The patient must have a confirmed stomach cancer diagnosis from a tissue sample taken after surgery, with a clear record o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07655024 · Guang'anmen Hospital of China Academy of Chinese Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇨🇳 CN

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed through laboratory testing of tissue samples - People whose cancer has been assessed by a surgeon as advanced and not ab...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07660627 · Masaryk Memorial Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇿 CZ

Who might be able to join this trial: - People who give their consent to take part in the study - People who have been diagnosed with cancer of the oesophagus (food pipe), stomach, or pancreas at an early stage (stage 0 to 2) - People with cancer that has not spread far but may be able to be removed with surgery, who a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07673887 · Astellas Pharma Global Development, Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 28 February 2031
Puerto Rico

Who might be able to join this trial: - People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus (called gastric or GEJ adenocarcinoma), confirmed by laboratory testing of a tissue or cell sample. - People whose cancer has been confirmed by scans to be advanced, unable...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07675967 · Dana-Farber Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2028
🇺🇸 US

Who might be able to join this trial: - You are an adult aged 18 or older - You have been diagnosed with one of the following cancers: breast, ovarian, lung, stomach, colorectal, esophageal, uterine, head and neck, or sarcoma - You have a plan in place to receive chemotherapy or radiation treatment for your cancer - Yo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07676461 · Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmie... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2029
🇨🇴 CO

**Who might be able to join this trial:** **For people with cancer:** - Adults aged 18 or older - People with a laboratory-confirmed diagnosis of advanced gastric (stomach), colorectal, breast, cervical, or head-and-neck cancer that has either spread to other parts of the body or cannot be removed by surgery - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07689851 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 July 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years, of any gender. - People who have been diagnosed with stomach (gastric) cancer or cancer at the junction of the stomach and food pipe (gastroesophageal junction), confirmed through tissue testing. - People whose cancer cannot be removed by surgery a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07705035 · Duboce Biopharmaceuticals, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 April 2030
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form - People who have a solid tumour that has been confirmed by laboratory testing of a tissue or cell sample, and that cannot be surgically removed, has come back, has spread locally, or has spread t...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07707531 · Huashan Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 30 April 2027
🇨🇳 CN

Who might be able to join this trial: - A written agreement to take part must be provided by the person themselves, their legal representative, or their caregiver. - People aged 18 years or older. - People who have been diagnosed with stomach cancer or pancreatic cancer through laboratory testing of tissue or cell samp...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Stomach Cancer. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Stomach cancer also falls under the Pancare Foundation's work on upper gastrointestinal cancers.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.